Pro Medicus Annual Report 2019

Plain-text annual report

Annual Report 2019 For personal use only 1. Highlights 2018/2019 3. CEO and Chairman’s Letter 5. Financial Summary 7. Business Background 9. Global Leadership Team 11. The Year in Review 13. Into the Future 15. Financial Report 16. Director’s Report 64. Director’s DeclarationCONTENTS 65. Independent Audit Report 71. ASX Additional Information 72. Corporate Governance 80. Corporate InformationPRO MEDICUS ANNUAL REPORT 20191HIGHLIGHTSFINANCIAL SUMMARY XNPAT $19.13 million – up 91.9% XUnderlying after-tax profit – $22.74 million - up 83.1% XRevenue of $50.11 million – increase of 47.9% XEBIT Margins increase to 51.6% XCash reserves of $32.32 million – up 28.0% XStrong balance sheet – debt free XDividends of 10.5c per share fully -franked – up 75.0%BUSINESS HIGHLIGHTS XTransaction revenue increased by 43.5% XTwo major contract wins – Partners Healthcare and Duke Health X5 out of the top 20 hospitals in the US have standardised on Visage 7 technology XImplementations on or ahead of schedule XFuture revenue increased to $180 million over next 5 years XAustralian and European businesses continued to perform well XStrong pipeline in terms of quantity and quality of opportunities For personal use only2 CEO & CHAIRMANletterdigitalPRO MEDICUS ANNUAL REPORT 20193digitalDear Shareholders,We are delighted to advise that 2019 has been another record year for the company with revenue rising by 47.9% to $50.11 million and underlying net profit after tax increasing by 83.1% to $22.74 million. A change in accounting standards regarding revenue recognition reduced the reported net profit after tax to $19.13 million which compared with the adjusted result for the prior year was an increase of 91.9%. The change also resulted in certain revenue being deferred to future periods and at 30 June 2019 the amount deferred was $22.91 million.This result was largely driven by the North American business which experienced strong growth in transaction revenue from new and existing customers. During the year, the company continued to expand its footprint in the North American market winning two key contracts. The first a $27 million contract with Partners Healthcare in November 2018, the company’s largest deal to date. This was followed by a $14 million contract with Duke Health in April 2019. As a result of these contract wins, five out of the top twenty hospitals in the US now use the company’s leading edge Visage 7 technology. Our Australian and European divisions were also solid contributors with further adoption of Visage RIS in Australia and a $3 million contract to a German government hospital in Europe.Our ongoing efforts and increasing investments in Research and Development for both our Visage 7 and Visage RIS products continue to be rewarded. The past year has also seen the company continue to enhance its reputation for successfully completing complex, large scale implementations in well under a quarter the time of the industry average. This has resulted in our clients realising significant benefits in key areas such as IT infrastructure consolidation, radiologist productivity, increased clinical accuracy and scalability. Furthermore, by reducing implementation risk we have been able to remove what was previously a significant barrier to change for many large health systems and are seeing this reflected in an increasing number of opportunities coming our way. The trend towards purchasing our technology on a transaction or “pay per view” basis continues with the majority of North American revenue now coming from this model. Based on committed minimum transaction numbers over a 5-7 year contract period, this model has built a high quality scalable annuity stream which grew 43.5% year on year as existing clients transaction volumes increase and we continue to implement the contracts we have won. We see this trend continuing in FY20 with Partners Healthcare and Duke coming on stream. The trends we have previously identified as driving the industry are continuing unabated. Exponentially growing data sets and the increasing importance of images as part of a patient’s electronic health record (EHR), are fueling industry adoption of new systems. Visage 7 with its fast, highly modular and scalable technology is uniquely suited to dealing with these challenges. We continue to see increasing interest in the new and exciting field of Artificial Intelligence (AI) whose technology shows real promise to improve radiological interpretation and workflow. Like all emerging technologies, wide scale adoption may take a while to achieve – but we believe we are extremely well positioned to take advantage of this trend as it develops. We finish the year financially stronger than ever with cash reserves of $32.32 million, up 28.0% from $25.24 million. As a result, we increased our dividends from 6.0 cents per share, fully franked, to 10.5 cents per share fully franked an increase of 75.0%. The company remains debt free and believes it has sufficient reserves to internally fund both the organic growth of the business and additionally invest strongly in its future.Key to this success are our staff. We thank them and our fellow directors for all their efforts throughout the year and look forward to an even brighter 2020.Yours faithfully Peter KempenDr Sam HupertPeter Kempen CHAIRMANSam Hupert CHIEF EXECUTIVE OFFICERFor personal use only4growth FINANCIALsummaryPRO MEDICUS ANNUAL REPORT 201952019 $’0002018 $’000(Restated)Revenues from Continuing Operations50,105+47.9%33,872Total Revenues 50,349+48.4%33,928Operating Profit Before Interest and Income Tax25,879+69.8%15,245Net Profit After Tax19,125+91.9%9,965Total Assets 30 June84,27861,043Shareholders’ Funds 30 June49,28835,069Net Tangible Assets per Share at 30 June (cents)24.016.0Earnings per Share (cents)18.5+90.7%9.7ALL FIGURES IN $A THOUSANDS UNLESS OTHERWISE STATEDYEAR ENDED 30 JUNE 2019YEAR ENDED 30 JUNE 2019For personal use only6 BUSINESSbackgroundafter taxprofitPRO MEDICUS ANNUAL REPORT 20197after taxprofitPro Medicus Limited [ASX: PME] is a leading health imaging IT provider. Founded in 1983, the company provides a comprehensive range of health imaging software and services to hospitals, imaging centres and health care groups. These solutions are branded “Visage” and provide one of the most comprehensive, enterprise- level, end-to-end offerings available in the radiology market today.VISAGE PRODUCTSThe Visage product line comprises solutions for RIS (Radiology Information Systems) / Practice Management, Healthcare Imaging and e-health. These systems can be used either individually or in combination by radiologists and other medical imaging professionals to interpret the images created by medical imaging equipment such as X-Ray and Ultrasound machines and CT and MRI Scanners and communicate the results to their referring clinicians.RIS AND PRACTICE MANAGEMENTPro Medicus offers software applications and services designed to aid the management of medical practices. The software includes medical accounting, clinical reporting, appointments/scheduling and marketing/management information modules and can be integrated with third-party applications. The Visage RIS provides radiology practices with a highly scalable, enterprise-level practice management solution that incorporates powerful search capability and configurable workflow and rules engines to meet a broad range of customer’s needs. Services include project management, implementation, training and ongoing technical and end-user support.HEALTHCARE IMAGINGIn January 2009, the company purchased Visage Imaging, which has been transformed into a global provider of leading-edge Enterprise imaging and 3D PACS (Picture Archiving and Communication System) solutions. The company’s Visage 7 product line incorporates highly optimised proprietary advanced visualization capability that delivers extremely fast, multi-dimensional images streamed via the Visage 7 intelligent thin-client viewer. Visage 7 components can either be combined and sold as an entire solution or individual components can be sold in a modular fashion as part of a best in breed offering.THE VISAGE 7 ENTERPRISE VIEWERThe Visage 7 Enterprise Viewer combines 3D/4D and advanced visualisation capabilities with the full gamut of 2D reading functionality creating a truly unique thin client streaming universal viewing platform. This enables radiologists to read any type of examination from a 2D chest x-ray to a complicated 3D cardiac study as well as view high-resolution photographic images and videos, all within the one viewer. The Enterprise viewer can be interfaced with a broad range of third-party vendor-neutral image archiving (VNA) databases and worklist products as part of a modular, interoperable solution. VISAGE 7 PACS As a result of the extensive R&D undertaken post the Visage Imaging acquisition, the Company has its own comprehensive 2D-3D/PACS offering which combines the Visage 7 Enterprise Viewer with the ability to store and archive radiological images using the Visage 7 Open Archive, creating one of the world’s first 3D PACS. The scalability and highly modular nature of the Visage 7 product offering means that our technology is ideally suited to the vast majority of radiology environments including large enterprise hospitals, private imaging centres and remote reading/teleradiology groups thus addressing segments of the radiology market previously not available or only partially accessible to us.VISAGE 7 AIRecent advances in machine learning, collectively known as Artificial Intelligence (AI), have made possible the development and use of algorithms that can recognise complex patterns in medical images.The Visage 7 platform uniquely combines both AI research and AI-assisted diagnostic interpretation in the same Enterprise Imaging platform. Visage 7 is powered by GPU’s which are the industry standard compute engine for AI. An open API enables third party to algorithms to be integrated into the Visage 7 platform.VISAGE EASE PRO Visage Ease Pro provides mobile app technology for diagnostic interpretation of medical images using iOS-based mobile devices. It is U.S. Food and Drug Administration (FDA) 510 (k) certified for all imaging modalities apart from mammography which requires higher screen resolution than current iOS devices can support. This enables clinicians to interpret images, no matter how large, anywhere using Visage technology. Visage Ease Pro includes numerous image manipulation features, display of non-DICOM (and non-diagnostic) images such as photos, support for recording voice memos, and the ability to upload photo attachments to studies on Visage 7.E-HEALTHThe Company’s Internet-based e-health offering, promedicus.net, enables referring doctors to receive encrypted clinical reports via the Internet to a centralised “in-tray” run on the doctor’s computer. These reports are then electronically incorporated into the patients’ medical records, doing away with the need for double handling or manual filing. Over 26,000 Australian doctors are registered users of promedicus.net.VISAGE 7 OPEN ARCHIVEThe Company introduced Visage 7 Open Archive to the North American market in May 2017 with the offering built on the same ultrafast, highly scalable enterprise imaging platform used in Visage 7. Coupled with a modular design based on open standards, Visage 7 Open Archive ensures maximum interoperability even in the most complex environments. The introduction of Visage 7 Open Archive enables the Company to offer the choice of modular or single-vendor solutions.For personal use only8global GLOBAL LEARDSHIPteamPRO MEDICUS ANNUAL REPORT 20199globalKEY PERSONNELBRAD LEVINGeneral Manager – North America and Global Head of Marketing MALTE WESTERHOFFGeneral Manager – Europe and Global Chief Technology OfficerBrad Levin’s broad experience has spanned a variety of leadership roles, including government, consulting, and marketing. While in government, Brad worked as a PACS subject matter expert for the U.S. Department of Defence’s Digital Imaging Network–Picture Archiving and Communications System (DIN-PACS) initiative, as well as consulting for top healthcare institutions across the U.S. After leaving his consulting role, Brad went on to spearhead marketing for two web-based PACS start-ups, first AMICAS, and then Dynamic Imaging. Both firms experienced rapid commercial growth leading to acquisition, by Vitalworks and GE Healthcare, respectively. In his most recent role, Brad was GE Healthcare’s Commercial Marketing Director, where he had radiology and cardiology marketing responsibility for their RIS, PACS and CVIT product portfolios.Malte Westerhoff is the General Manager for Visage Imaging GmbH, the European branch of Visage Imaging. He is also the company Chief Technical Officer (CTO) and is responsible for product management and R&D globally. He has more than fifteen years of experience in medical imaging and software development, holding positions in both research and industry. Malte holds a master’s degree in physics from Technical University, Berlin, and a Ph.D. in computer science and mathematics from Free University, Berlin. Malte was one of the founders of Indeed - Visual Concepts GmbH the precursor to Visage Imaging and is an author/co-author of several papers in scientific visualization and high-performance computing. In the role as CTO, he is involved in developing and overseeing the company’s growing intellectual property patent portfolio. Before joining Pro Medicus, he served in senior technical leadership positions at Mercury Computer Systems and Indeed - Visual Concepts. SEAN LAMBRIGHTGlobal Head of SalesSean Lambright is the Global Head of Sales for Visage Imaging as well as VP Sales, North America. He is responsible for the company’s global sales strategy, including all third-party and channel relationships. Sean joined Visage in 2010 and has been instrumental in positioning Visage as a complete enterprise imaging solution capable of dealing with some of the largest and most prestigious health systems in North America. Prior to Visage, his career in imaging IT has spanned 17 years, having served in senior sales roles with AGFA Healthcare, AMICAS and Emageon.Sean holds a Bachelor of Science degree from Arizona State University.In 2015 the company transitioned from a Regional to a Global management structure appointing four regional managers to global roles in the areas of Technology/R&D, Sales, Marketing, and Customer Services. The 2019 financial year has been the most successful in the company’s history confirming the board’s belief that this structure has served the company well and positions us to cater for anticipated future growth.DANNY TAUBERGeneral Manager – AustraliaDanny Tauber joined Pro Medicus in 1993 after a diverse career in accounting, property development and IT. Assuming the role of General Manager – Australia in 2011 he is recognised as an industry expert and leads our Australian operation, which includes software development, application support and professional services.TERESA GSCHWINDGlobal Head of Customer ServiceTeresa Gschwind is the Global Head of Customer Service for Visage Imaging, where she is responsible for pre- and post-sales customer service activities worldwide. Prior to this role, Teresa managed the Company’s U.S. Customer Service team based in MA, and then the European Customer Service team based in Berlin, Germany. Teresa has extensive experience working with Visage’s global customer base, having joined the Company in 2002 when Visage was part of Mercury Computer Systems. Prior to Visage, Teresa held numerous management positions at Datacube, Inc, where she specialized in image processing.Teresa holds a Bachelor of Science degree in Electrical Engineering from the University of New Hampshire.For personal use only10 THE YEAR INreviewUSeuropeaustraliaPRO MEDICUS ANNUAL REPORT 201911europeaustraliaAUSTRALIAThe company’s Australian operation undertakes research and development of the Visage RIS and e-health products as well as sales and service/support functions of both Visage RIS and Visage 7 products.Australian revenue increased by 30.2% from the previous year driven by the progressive implementation of Visage RIS fulfilling long term (5-year) contracts with I-MED Network Radiology and Healius (previously known as Primary Health Care) as well as winning new customers.Promedicus.net, the company’s e-health offering experienced modest growth throughout the year despite increasing competition. NORTH AMERICAThe company’s North American team comprising sales, marketing, implementation and service/support staff was a strong contributor to the group’s overall performance with revenue growing by 42.2% compared to the previous year. This was attributable to continued growth in transaction-based revenue as existing client’s transaction volumes increased, and previously won contracts came on stream. New Contract wins / extensions / renewalsJuly 2018 - a $5M, seven-year transaction-based deal with Carle Foundation Hospital, a regional health system in Urbana, Illinois. November 2018 - The Company won its biggest contract to date, a 7-year, $27M deal with Partners Healthcare (Partners). Partners founded in 1994 by Massachusetts General Hospital (“MGH”) and Brigham and Women’s Hospital (“BWH”) is the largest health system in the state of Massachusetts and one of the largest and most respected health providers in North America. Partners is also a national leader in biomedical and data science research, including the MGH & BWH Center for Clinical Data Science. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented at Partners’ two flagship hospital systems, MGH and BWH with scope to expand to other Partners network hospitals at a later date. February 2019 - The Veteran Affairs (VA) Midwest Health Care Network (VISN 23) renewed its contract for its eleven-hospital network for another 5 years.April 2019 - Duke Health (Duke), the largest health system in the state of North Carolina and one of the country’s leading academic institutions, signed a 7 year, $14M contract with the company. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented across all of Duke’s radiology departments and integrated to Duke’s electronic health record (EHR).Implementations – on or ahead of scheduleThe past year, saw the company build on its track record of highly optimised implementations, completing a number of large scale implementations in well under a quarter to a fifth the time of the industry average.This has resulted in our clients realising significant benefits in key areas such as IT infrastructure consolidation, radiologist productivity, increased clinical accuracy and scalability all of which have significantly enhanced Visage’s value proposition.Furthermore, by reducing implementation risk we have been able to remove what was previously a significant barrier to change for many large health systems and are seeing this reflected in an increasing number of opportunities coming to market. EUROPEThe Group’s employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group’s European operations. Revenue from our European operations increased by 102.3% from the previous year. December 2018 - The Company announced the signing of an extension to the contract it has with a large German Government Hospital network. The deal, which includes additional licenses for the existing site, will also see Visage 7 and Visage 7 Open Archive serve as the central components of a next-generation imaging infrastructure at two additional hospitals within the network. COMPANY OFFICESIN ADDITION TO ITS MELBOURNE-BASED AUSTRALIAN HEAD OFFICE, THE COMPANY HAS TWO OFFSHORE OFFICES:VISAGE GMBH – BERLINThis is the company’s European headquarters and houses employees who are primarily involved in product R&D and ongoing product support. This office also forms the base of the company’s European operations including order administration and both direct and OEM sales activities.VISAGE IMAGING INC – SAN DIEGOThis is the company’s North American headquarters and is the base for staff involved in sales, marketing, training/implementation and applications support for both the Visage Imaging and Pro Medicus products.For personal use only12futureIS NOW INTO THEfuture• EXPANDED PRODUCT PORTFOLIO• VISAGE 7 OPEN ARCHIVE• GROUND BREAKING VISAGE 7 TECHNOLOGY• ADDRESSING ENTERPRISE/HOSPITAL MARKETS• CONTINUED US EXPANSION• NEW RIS TECHNOLOGY PLATFORM• PAY PER USE LICENSING MODEL• ENTERPRISE IMAGING• ARTIFICIAL INTELLIGENCEPRO MEDICUS ANNUAL REPORT 201913futureThe Board and Management believe the Company is extremely well-positioned for growth after making strong progress in the 2019 financial year. Key factors predicted to drive growth include:EXPANDED GEOGRAPHICAL FOOTPRINTOver the past year, the company continued to build on its presence in North America and Australia as well as consolidate its position in Europe. Our growing North American customer base comprises some of the largest and most prestigious health systems in the U.S., including 5 of the top 20 ranked hospitals in the U.S. for 2019/20 (U.S. News & World Report Honour Roll).The company believes it can continue to leverage its expanded footprint and increased market presence to drive further sales opportunities across all segments of the market including large Enterprise hospitals, private imaging centres and remote reading teleradiology.HIGHLY DIFFERENTIATED TECHNOLOGYThe Company continues to maintain its significant ongoing investment in R&D for its flagship Visage 7 suite of products, which includes the Visage 7 Viewer and Visage 7 Open Archive, which we believe will continue to differentiate our offerings in the modular PACS, Enterprise viewer, 3D PACS and advanced visualisation space.The Visage RIS platform is the culmination of many years of intense R&D effort and positions Pro Medicus at the forefront of RIS/Practice Management technology. It is differentiated by its scalability, powerful search capability and ability to allow clients to configure their business-specific workflow and rules to meet their needs.INDUSTRY TRENDSThe Company believes the North American market has reached a tipping point as a result of a number of significant industry trends that when combined, continue to drive demand for Visage 7 products. Adoption of Electronic Health Records (EHR)The US Government as part of its Meaningful Use program has mandated US health institutions to implement an enterprise-wide Electronic Health Record (EHR) Under this new model, all patient clinical data including images is entered into, and is accessed via, the EHR. This has resulted in a heightened focus on enterprise imaging as medical images both DICOM (radiology and cardiology) as well as non DICOM (photos and videos) now comprise a large and rapidly growing part of the medical record.Visage 7, with its ability to display all of these image types within the one product, is well positioned to benefit from this rapidly evolving trend.Explosion in image data size continuesWith developments in imaging technology it is now common for a single examination image file to be in the order of 1.5 to 2 Gigabytes or larger. The introduction of Digital Breast Tomosynthesis (DBT), a new form of 3D breast imaging, has added to the data explosion problem producing image files as large as 6 to 10 Gigabytes per examination. Traditional PACS/Digital Imaging technology requires these files to be transferred across the network to the radiologist desktop to be visualised. This has created very significant network bottlenecks which have limited the widespread adoption and use of these new imaging technologies. Visage 7, with its unique server-side thin-client streaming technology, enables the radiologist or referring clinician to instantly visualize these very large datasets without having to move the images to their desktop thereby overcoming the bandwidth/ network bottleneck issue. The move to interoperable, best in breed SolutionsIncreasingly sales opportunities are requesting a modular or “best in breed” approach whereby multiple components from different vendors are integrated into a single solution. Unlike systems from traditional PACS vendors, Visage 7, with its highly modular and scalable design is ideally suited to this new paradigm resulting in a growing pipeline of opportunities that the company is actively pursuing.Artificial Intelligence (AI)Few trends have garnered as much interest as machine learning or Artificial Intelligence (AI) has to the field of Healthcare Imaging. Like all emerging technologies, wide scale adoption may take a while to achieve – but we believe the company is extremely well positioned to take advantage of this trend as it develops. TRANSACTION BASED LICENCING The vast majority of the company’s contracts are now transaction or “pay per view” based. This not only enables customers to more accurately align their investment in Visage to the size of their business, but has the added benefit of creating significant ongoing revenue streams for the company.ENTERPRISE IMAGINGThe company has made significant investments in ongoing R&D to develop products including Visage 7 Enterprise. This new product extends the capability of Visage 7 beyond the realm of radiology enabling the viewing of DICOM (radiology) and non-DICOM images such as photos and HD videos (also described as medical multimedia objects) all in the one viewer. Examples of this include wound care photos taken at the bedside, ophthalmology images, dermatology images, as well as video (endoscopic, arthroscopic, operating room HD-video).NEW PRODUCTS AND SERVICESAs our customer base continues to grow so dos the opportunity for on-selling additional, complementary products and services. An increasing proportion of the company’s R&D effort is focused on developing such as complementary services and products which we believe will further increase our value proposition for our large enterprise clients. INTO THEfuture• EXPANDED PRODUCT PORTFOLIO• VISAGE 7 OPEN ARCHIVE• GROUND BREAKING VISAGE 7 TECHNOLOGY• ADDRESSING ENTERPRISE/HOSPITAL MARKETS• CONTINUED US EXPANSION• NEW RIS TECHNOLOGY PLATFORM• PAY PER USE LICENSING MODEL• ENTERPRISE IMAGING• ARTIFICIAL INTELLIGENCEFor personal use only14after taxprofit FINANCIALreportPRO MEDICUS ANNUAL REPORT 201915after taxprofitANNUAL FINANCIAL REPORT 30 JUNE 2019Directors’ Report16Auditor’s Independence Declaration27Statement of Comprehensive Income28Statement of Financial Position29Statement of Changes in Equity30Statement of Cash Flows31Notes to the Financial Statements32Note1Corporate Information32Note2Summary of Significant Accounting Policies32Note3Significant Accounting Judgements, Estimates and Assumptions36Note4Operating Segments37Note5Revenue from contracts with customers39Note6Income and Expenses40Note7Income Tax41Note8Earnings per Share43Note9Dividends Paid and Proposed44Note10Cash and Cash Equivalents45Note11Trade and Other Receivables 46Note12Inventory47Note13Plant and Equipment47Note14Intangible Assets48Note15Trade and Other Payables 50Note16Deferred Revenue50Note17Provisions51Note18Contributed Equity and Reserves 51Note19Share based Payments 52Note20Commitments 55Note21Events after the Balance Sheet Date56Note22Auditors’ Remuneration56Note23Key Management Personnel56Note24Related Party Disclosure57Note25Financial Risk Management Objectives and Policies58Note26Contingencies61Note27Parent Entity Information61Note28Other Accounting Policies62Directors’ Declaration64Independent Auditor’s Report65ASX Additional Information71Corporate Governance Statement72Corporate Information80ANNUAL FINANCIAL REPORT 30 JUNE 2019For personal use only16DR SAM AARON HUPERTM.B.B.S.Managing Director and Chief Executive OfficerCo-founder of Pro Medicus Limited in 1983, Sam Hupert is a Monash University Medical School graduate who commenced General Practice in 1980. Realising the significant potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing the Group.Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.DIRECTORS’reportYour Directors submit their report for the year ended 30 June 2019 in relation to Pro Medicus Limited (the “Company”) and its subsidiaries (the “Group”).DIRECTORS The names and details of the Company’s Directors in office during the financial year and until the date of this report are as follows:ANTHONY JAMES GLENNINGB.CS, B.EE, M.EENon-Executive DirectorAnthony joined Pro Medicus Limited as a Director on 1 May 2016. He is the fund manager of Skalata Ventures, investing in early stage companies to help them scale and grow into significant and sustainable businesses.He is a Director of Azure Healthcare Limited (ASX:AZV), an international provider of healthcare communication and clinical workflow management solutions. He is also Chairman of Cyrise Pty Ltd, an accelerator for early stage cyber security start-ups.Anthony has previously been Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems.Anthony holds bachelor degrees in Computer Science and Electrical Engineering from University of Melbourne and holds a Master’s degree in Electrical Engineering from Stanford University California.Anthony also serves on the audit committee.PETER TERENCE KEMPENAM, F.C.A, F.A.I.C.D(Chairman)Peter Kempen joined Pro Medicus Limited as a Director on 12 March 2008. He is Chairman of Australasian Leukaemia and Lymphoma Group and Chairman of Logie- Smith Lanyon. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda’s College Ltd, University of Melbourne.Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia.Peter is a Fellow of the Institute of Chartered Accountants in Australia and a Fellow of the Australian Institute of Company Directors. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen’s Birthday Honours.Peter became Chairman in August 2010 before which he served as a Non-Executive Director of the Company.Peter is also Chairman of the audit committee.CLAYTON JAMES HATCHCPACompany SecetaryClayton was appointed Company Secretary on 1 July 2009. Clayton has strong experience in financial and management accounting having worked in a Finance role for several years. Clayton joined Pro Medicus in June 2008 and has progressed through the Company to his current position of Chief Financial Officer which he assumed on 1 July 2012. ANTHONY BARRY HALLB.Sc. (Hons), M.Sc.Executive Director and Technology DirectorCo-founder of Pro Medicus Limited in 1983, Anthony Hall has been principal architect and developer of the core software systems. His current focus is the transition to and development of the Company’s next generation RIS systems.Anthony holds a Bachelor and Master’s degree in Science from La Trobe University.DR LEIGH FARRELLPhD, B.Sc. (Hons), FAICDNon-Executive Director(Appointed 8 September 2017)Leigh joined Pro Medicus Limited as a Director on 8 September 2017. He is Senior Vice President, Commercial of Certara USA, Inc. and prior to his current position he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh holds a PhD in Biochemistry and a Bachelor of Science (Honours) from Monash University and is a Fellow of the Australian Institute of Company Directors.Leigh also serves on the audit committee.DIRECTORS’reportPRO MEDICUS ANNUAL REPORT 201917OPERATING AND FINANCIAL REVIEWINTERESTS IN THE SHARES AND OPTIONS OF THE COMPANYAs at the date of this report, the interests of the Directors in the shares and options of the Company were:Ordinary SharesOptions over Ordinary SharesA. B. Hall29,067,500NILS. A. Hupert29,107,660NILP. T. Kempen678,082NILA. J. Glenning4,000NILL. Farrell2,501NILEARNINGS PER SHARE CentsBasic earnings per share18.46Diluted earnings per share18.32DIVIDENDSORDINARY SHARESCENTS$’000Final dividends recommended: Normal dividend plan4.54,663Dividends paid in the year: Interim for the year3.53,627 Advance final dividend 2.52,590Final dividend for 2018 shown as recommended in the 2018 report: Normal dividend plan3.53,618CORPORATE STRUCTUREPro Medicus Limited is a company limited by shares that is incorporated and domiciled in Australia. Nature of operations and principal activities The principal activities of the Group during the year were the supply of healthcare imaging software and services to hospitals, diagnostic imaging groups and other health related entities in Australia, North America and Europe. These products and services include:Radiology Information Systems (RIS) ▶Proprietary medical software for practice management (RIS); ▶Training, installation and professional services; ▶After sale support and service products; ▶Promedicus.net secure email; and ▶Integration products.Visage 7.0 ▶Healthcare imaging software that provides radiologist and clinicians with advanced visualisation capability for rapidly viewing 2-D, 3-D and 4-D medical images; ▶PACS/Digital imaging software that is sold directly and to original equipment manufacturers (OEM); ▶Training, installation and professional services; and ▶Service and support products.The Group has continued development of both the RIS products and the Visage 7.0 product line throughout the period.The Group undertakes research and development (R&D) in Australia for its Practice Management (RIS) and promedicus.net products including R&D for Visage RIS, its new technology platform.The R&D for the Visage Imaging product set is carried out in Europe.For personal use only18REVIEW AND RESULTS OF OPERATIONS Investment ActivitiesSurplus funds which are held in several currencies are invested by the Group in a cash management account and term deposits to maximise the interest return. Performance IndicatorsManagement and the Board monitor overall performance, from the strategic plan through to the performance of the Group against operating plans and financial budgets.The Board, together with management, have identified key performance indicators (KPIs) that are used to monitor performance. Key management monitor these KPIs on a regular basis and Directors receive appropriately structured board reports for review prior to each monthly Board meeting allowing them to actively monitor the Group’s performance.Dynamics of the BusinessAustraliaThe Group’s Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.The Group’s Australian revenue increased by 30.2% compared to the previous year, with the rollout of the Healius (ex Primary Health) contract and extension of its contract with I-MED being the main contributors to the increased revenue.Promedicus.net, the company’s e-health offering, continued to hold its market position despite increasing competition. North AmericaThe North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 42.2% compared to the previous year. This was attributable to increase in transaction based revenue from sales of Visage technology as more contracts came on stream and the migration and implementation of Visage Open Archive to Mercy Health.EuropeThe Group’s employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group’s European operations. Revenue for software from our European operations increased by 102.3% from the previous year, after extending its contract with a sale of $3.049m with the German government.FinancialsReported profit after tax for the period was $19.13m an increase of 91.9% (restated) from the previous year.Full year revenue of the Group increased from $33.87m (restated) to $50.11m, an increase of 47.9%. As the Group’s costs are relatively fixed, an increase in sales has a significant impact on profitability.The key drivers of the profit increase were the significant increase in the performance of all geographical segments, with increased transactions in North American and European operations, as well as increased RIS sales in Australia.The result from the underlying operations for the year was a profit of $22.74m compared to an underlying profit of $12.42m from the previous corresponding period, an increase of 83.1%. The underlying profit comprises reported profit after tax of $19.13m less the after tax net currency gain of $0.29m and adding back the impact of the new revenue recognition standard of $3.90m (refer to Note 2(d)(i) in the financial statements for details on the impact of AASB 15 Revenue from Contracts with Customers). The underlying profit from 2018, comprises of reported profit after tax of $9.96m less the after tax currency gain of $0.32m and adding back the impact of the new revenue recognition standard of $2.78m.During the period the Company continued to make strong inroads into the North American market winning a key $27.0m contract with Partners Healthcare, the largest health system in the state of Massachusetts and one of the largest and most respected health providers in North America. The Company also won a key contract with Duke Health for $14.0m, the largest health system in North Carolina and one of the most respected health providers in North America.Investments for Future PerformanceThe Company will continue to direct resources into the development of new products and is committed to the continued development of its Visage RIS and Visage 7.0 product sets.It is anticipated that this strategy of ongoing development will continue to position Pro Medicus as a market leader and enable the Group to further leverage its expanded product portfolio and geographical spread. The Group remains committed to providing staff with access to appropriate training and development programs, together with the resources to complete their duties.The Directors express their gratitude for the efforts of the management team and all employees in achieving this year’s result.REVIEW OF FINANCIAL CONDITIONCapital StructureThe Company has a sound capital structure with a strong financial position and is debt free.DIRECTORS’ REPORT CONT.PRO MEDICUS ANNUAL REPORT 201919Treasury PolicyThe treasury function, co-ordinated within Pro Medicus Limited, is limited to maximising interest return on surplus funds and managing currency risk. The treasury function operates within policies set by the Board, which is responsible for ensuring that management’s actions are in line with Board policy. With the increase in overseas operations there is an increased currency risk as a consequence of contracts written in and cash being held in foreign currencies. Whilst this is offset to a degree by having operations in North America and Europe, this change in risk profile has been noted by the Board and steps have been taken to manage this risk.Cash from OperationsNet cash flows from operating activities for the current period was a positive $24.66m, with receipts from customers totalling $47.76m compared with payments of $15.81m to suppliers and employees. During the year the Company paid out a total of $9.84m in dividends, the net result being total cash assets of $32.32m; an increase of 28.0% from last year.Liquidity and FundingThe Group is cash flow positive, has adequate cash reserves and has no overdraft facility. Sufficient funds are held to finance operations.Risk ManagementThe Company takes a proactive approach to risk management. The Board is responsible for ensuring that risks, and also opportunities, are identified on a timely basis and that the Group’s objectives and activities are aligned with the risks and opportunities identified by the Board.The Company believes that it is crucial for all Board members to participate in this process, as such the Board has not established separate committees for areas such as risk management, environmental issues, occupational health and safety or treasury.The Board has a number of mechanisms in place to ensure that management’s objectives and activities are aligned with the risks identified by the Board. These include the following:• Board approval of strategic plans, which encompass the Company’s vision, mission and strategy statements, designed to meet stakeholder needs and manage business risk;• Implementation of Board approved operating plans and budgets and Board monitoring of progress against these budgets, including the establishment and monitoring of KPIs; • Overseeing of appropriate backup procedures for important company data; and• Routine review by key executives of its established Quality Assurance program and corrective action recommendations stemming from it.Corporate GovernanceIn recognising the need for the highest standards of corporate behaviour and accountability, the Directors of Pro Medicus Limited support and have adhered to the principles of good corporate governance. Please refer to the separate “Corporate Governance” section for more details of specific policies.SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS Shareholders’ equity increased by 40.5% from $35.07m (restated) to $49.29m. This movement was largely the result of profit during the year, offset by dividends paid out during the year.SIGNIFICANT EVENTS AFTER THE BALANCE DATE A Final Dividend of 4.5 cents per share has been declared post 30 June 2019. Please refer to Note 9 of the financial statements.LIKELY DEVELOPMENTS AND EXPECTED RESULTS The Directors anticipate that the 2020 financial year will see more opportunities crystallise for the company due to improved prospects in North America and the continued commercialisation and roll out of Visage RIS, the company’s new technology RIS platform.Key components that are likely to affect the performance of the company are:• Increased revenue being generated from previously won transaction based contracts which are scheduled to come on stream in the 2020 financial year.• Continued strong interest in the Visage 7.0 suite of products in the North American market has resulted in a number of sales opportunities that the Company is actively pursuing.• The ability of the expanded Visage 7.0 product set to address key market segments such as large Health Systems and Hospitals in addition to the private radiology and teleradiology markets. • Market dynamics that favour the adoption of Visage 7.0 technology such as trend towards modular, best in breed solutions.• Increased revenue from Visage RIS, the company’s new technology RIS platform as the rollout of this new platform continues.As a result, it is anticipated that the 2020 financial year will show a continuing improvement in operational results, however this is dependent upon many market factors over which the Directors have limited or no control. For personal use only20ENVIRONMENTAL REGULATION AND PERFORMANCE The Group has no identified risk with regard to environmental regulations currently in force. There have been no known breaches by the Group of any regulations.SHARE OPTIONS Un-issued SharesAs at the date of this report, there were zero un-issued ordinary shares under options. Refer to Note 19 of the financial statements for further details of movement of options throughout the year.Shares Issued as a Result of the Exercise of OptionsDuring the financial year, zero share options were exercised by current employees to acquire fully paid ordinary shares in Pro Medicus Limited and no share options expired. PERFORMANCE RIGHTSUn-issued SharesAs at the date of this report, there were 1,200,390 un-issued ordinary shares under performance rights. Refer to Note 19 of the financial statements for further details of the performance rights outstanding.Rights holders do not have any right, by virtue of the right, to participate in any share issue of the Company.Shares Issued as a Result of the Exercise of Performance RightsDuring the financial year, 120,906 performance rights were exercised by current employees and no performance rights expired. A further 126,563 performance rights were exercised by key management personnel in the current year to acquire fully paid ordinary shares in Pro Medicus Limited. INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS During or since the financial year, the Company has paid premiums in respect of a contract for Directors’ & Officers’/Company Re-Imbursement Liability insurance for directors, officers and Pro Medicus Limited for costs incurred in defending proceedings against them. Disclosure of the amount of insurance and the terms of this cover is prohibited by the insurance policy.INDEMNIFICATION OF AUDITORS To the extent permitted by law, the Company has agreed to indemnify its auditors, Ernst & Young, as part of the terms of its audit engagement agreement against claims by third parties arising from the audit (for an unspecified amount). No payment has been made to indemnify Ernst & Young during or since the financial year.REMUNERATION REPORT (AUDITED)This remuneration report for the year ended 30 June 2019 outlines the remuneration arrangements of the Group in accordance with the requirements of the Corporations Act 2001 and its Regulations. This information has been audited as required by section 308(3C) of the Act.The remuneration report details the remuneration arrangements for key management personnel (KMP) who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company and the Group, directly or indirectly, including any director (whether executive or otherwise) of the Group.For the purposes of this report, the term ‘executive’ includes the Chief Executive Officer (CEO), Executive Directors and other Senior Executives whom are considered KMP of the Group.(i) Non- Executive DirectorsPeter Terence Kempen Chairman Anthony Glenning Director (non-executive)Leigh Farrell Director (non-executive)(ii) Executive DirectorsDr Sam Aaron Hupert Managing Director and CEOAnthony Barry Hall Technology Director(iii) Other Senior ExecutivesDanny Tauber General Manager – Pro Medicus LimitedMalte Westerhoff Managing Director – Visage Imaging GmbH Brad Levin General Manager – Visage Imaging Inc.Sean Lambright Global Head of Sales – Visage Imaging Inc.Remuneration and nomination issues are handled at the full Board level. Due to the small number of Directors no committee has been established for this purpose. Board members, as per groupings detailed below, are responsible for determining and reviewing compensation arrangements.In order to maintain good corporate governance the Non-Executive Directors assume responsibility for determining and reviewing compensation arrangements for the Executive Directors of the Group. The Executive Directors in turn are responsible for determining and reviewing the compensation arrangements for the Non-Executive Directors. The CEO, in conjunction with the full Board reviews the terms of employment for all executives.The remuneration assessment considers the appropriateness of the nature and amount of remuneration of such executives on a periodic DIRECTORS’ REPORT CONT.PRO MEDICUS ANNUAL REPORT 201921basis by reference to relevant employment market conditions with the overall objective of ensuring maximum stakeholder benefit from the retention of a high quality Board and executive team. Remuneration PhilosophyThe performance of the Group depends upon the quality of its Directors and Executives. To prosper, the Group must attract, motivate and retain highly skilled Directors and Executives.To this end, the Group provides competitive rewards to attract high calibre Executives.Remuneration StructureIn accordance with best practice corporate governance, the structure of Non-Executive Director and Executive remuneration is separate and distinct.Non-Executive Director RemunerationObjectiveThe Board seeks to set aggregate remuneration at a level which provides the Company with the ability to attract and retain Directors of the highest calibre, whilst incurring a cost which is acceptable to shareholders.StructureThe Constitution and the ASX Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be determined from time to time by a general meeting. An amount not exceeding the amount determined is then divided between the Non-Executive Directors as agreed. The latest determination was at the Annual General Meeting held on 4 November 2005 when shareholders approved an aggregate remuneration of $500,000 per year.The amount of the aggregate remuneration sought to be approved by shareholders and the manner in which it is apportioned amongst Non-Executive Directors is reviewed annually. The Board considers fees paid to Non-Executive Directors of comparable companies when undertaking the annual review process.Each Non-Executive Director receives a fee for being a Director of the Company. No additional fee is paid for time spent on Audit Committee business.Non-Executive Directors have long been encouraged by the Board to hold shares in the Company (purchased by the Non-Executive Director on market). It is considered good governance for the Non-Executive Directors to have a stake in the Company on whose Board they sit. The remuneration of Non-Executive Directors for the period ended 30 June 2019 is detailed in Table 1 of this report.Executives RemunerationObjectiveThe Group aims to reward Executives with a level and mix of remuneration commensurate with their position and responsibilities within the Group and so as to:• align the interests of Executives with those of shareholders; and• ensure total remuneration is competitive by market standards.StructureEmployment contracts have been entered into with all Executives of the Group. Details of these contracts are provided on page 23.Remuneration consists predominately of fixed remuneration. Variable remuneration is provided occasionally at the Board’s discretion including both short term incentives (STI) and long term incentives (LTI).The Company does not have a policy regarding Executives entering into contracts to hedge their exposure to share options granted as part of their remuneration package. Fixed RemunerationObjectiveThe level of fixed remuneration is set so as to provide a base level of remuneration which is both appropriate to the position and is competitive in the market.Fixed remuneration is reviewed annually and the process consists of a review of Group-wide business and individual performance, relevant comparative remuneration in the market and internal and, where appropriate, external advice on policies and practices.Executives, including Executive Directors, are given the opportunity to receive their fixed (primary) remuneration in a variety of forms including cash and fringe benefits such as motor vehicles and expense payment plans. It is intended that the manner of payment chosen will be optimal for the recipient without creating undue cost for the Group.The fixed remuneration is detailed in Table 1 of this report.For personal use only22Variable Remuneration – Long Term Incentive (LTI)Performance RightsFormer LTI Plan – Granted until FY2017A long term incentive plan was established during 2011-12 whereby Senior Executives of the Group were offered performance rights over the ordinary shares of Pro Medicus Limited. The performance rights, issued for nil consideration, were offered over a 5 year period and vest 4 years after grant date on completion of service. This long term incentive plan includes performance hurdles related to profitability (EBIT – 75%) which was set on an annualised basis by the Board and individual performance (25%). These measures have been selected and set to align to Company performance and to reflect individual contribution to the Company.The fair value of the equity-settled performance rights is estimated using a Black-Scholes model at grant date taking into account the terms and conditions upon which the performance rights were granted. For further details of valuation of options, models and assumptions used, refer to Note 19 of the financial statements.The table below outlines the proportion to target of performance rights that were granted based on performance measures since the plan was established. No new grants were awarded during the year ended 30 June 2019 and 2018 under this long term incentive plan.2019201820172016201575% EBIT targets metN/AN/A125%85%25%25% Individual targets metN/AN/A83%88%92%A share-based payment expense continues to be provided to certain Executives during the year ended 30 June 2019 related to unvested tranches of this long term incentive plan.Current LTI Plan – Granted from FY2017A new long term incentive plan was established during 2016-17 whereby Senior Executives of the Group were offered performance rights over the ordinary shares of Pro Medicus Limited. The performance rights, issued for nil consideration, are offered over a 5 year period and vest 4 years after grant date on completion of service. This long term incentive plan includes performance hurdles related to profitability - Earnings per Share (EPS) growth (60%) which is set on an annualised basis by the Board and Total Shareholder Returns (TSR) growth (40%). The Company’s TSR growth performance hurdle is measured relative to the ASX300 Index and assessed by the Board at the end of the performance period in accordance with the terms of the plan. These measures have been selected and set to align to Company performance and shareholder value.The fair value of the equity-settled performance rights is estimated using Black Sholes and Monte Carlo Simulation Models at grant date taking into account the terms and conditions upon which the performance rights were granted. For further details of valuation of options, models and assumptions used please refer to Note 19 of the financial statements. Grants of performance rights under the current LTI Plan have not yet vested.Variable Remuneration – Short Term Incentive (STI)Short term incentives in the form of cash bonuses were paid to Executives based on a mix of Company based and personal performance targets.STI bonus for 2019The table below outlines the proportion to target of STI cash bonuses provided since the new STI plan was established2019201820172016201575% EBIT targets met200%35%125%N/AN/A25% Individual targets met100%*143%91%N/AN/A* Accrued in the financial statements at 100%, to be determined at a later date by the Board.Key Performance IndicatorsActual STI payments granted to Executives under the individual target portion, depended on the extent to which specific targets set at the time of employment were met. The targets consist of a number of Key Performance Indicators (KPIs) covering both financial (Sales Targets) and non-financial measures of performance, including client satisfaction, patent filings and employee satisfaction.DIRECTORS’ REPORT CONT.PRO MEDICUS ANNUAL REPORT 201923Shareholder ReturnsThe Directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the Company as the business looks to increase its penetration of existing markets.The return on net assets and equity are shown in the table below.20192018 (restated)201720162015Basic earnings per share – reported (cents)18.59.79.16.33.2Return on assets (%)31.025.128.624.317.6Return on equity (%)38.828.426.823.314.7Dividend payout ratio (%) – normal dividend plan57.162.144.047.962.3Dividend payout ratio (%) – total dividend57.162.144.047.962.3Available franking credits ($’000)2,41782053100Employment ContractsExecutive DirectorsExecutive Service Contracts, on similar terms and conditions, have been prepared for all Executive Directors of the Company. These agreements provide the following major terms:• Each Executive will receive a remuneration package per annum which is to be reviewed annually;• The agreements protect the Company and Group’s confidential information and provide that any inventions or discoveries of an Executive become the property of the Group;• Non-competition during employment and for a period of 12 months thereafter; and• Termination by the Company on six months’ notice or payment of six months remuneration in lieu of notice or a combination of both (or without notice or payment in lieu in the event of misconduct or other specified circumstances). The agreements may be terminated by the Executives on the giving of six months’ notice.Executives (excluding Executive Directors)All Executives have rolling contracts. The Group may terminate the Executive’s employment agreement by providing six months written notice or providing payment in lieu of the notice period (based on the fixed component of the Executive’s remuneration). The Group may terminate the contract at any time without notice if serious misconduct has occurred. Where termination with cause occurs the Executive is only entitled to that portion of remuneration that is fixed, and only up to the date of termination. On termination with cause any unvested options will immediately be forfeited.Table 1: Remuneration of key management personnel for the year ended 30 June 2019Short-TermPost- EmploymentLong- TermShare- Based PaymentTotalTotal Performance Related (%)30 June 2019($)Salary and FeesCash BonusNon-Monetary benefitsSuper annuationLong Service LeavePerformance RightsDirectorsP T Kempen73,943-1,05725,000--100,000-S A Hupert475,000--25,0007,916-507,916-A B Hall349,440--25,0005,833-380,273-A Glenning91,324--8,676--100,000-L Farrell82,192--7,808--90,000-ExecutivesD Tauber329,46991,875-20,49111,643106,936560,41435.5%M Westerhoff460,642331,55919,4152,794-285,1861,099,59656.1%B Levin307,626195,631---88,826592,08348.0%S Lambright237,711431,893---26,695696,29965.9%2,407,3471,050,95820,472114,76925,392507,6434,126,581For personal use only24Compensation options granted, vested and exercised during the year as part of remuneration During the reporting period, 15,384 rights with a fair value of $45,844 (TSR hurdle - $1.10, EPS hurdle - $4.24 per performance right) were granted as performance rights to Danny Tauber with a grant date of 16 August 2018 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 45,306 rights with a fair value of $135,012 (TSR hurdle - $1.10, EPS hurdle - $4.24 per performance right) were granted as performance rights to Malte Westerhoff with a grant date of 16 August 2018 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 13,910 rights with a fair value of $41,452 (TSR hurdle - $1.10, EPS hurdle - $4.24 per performance right) were granted as performance rights to Brad Levin with a grant date of 16 August 2018 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 10,748 rights with a fair value of $32,029 (TSR hurdle - $1.10, EPS hurdle - $4.24 per performance right) were granted as performance rights to Sean Lambright with a grant date of 16 August 2018 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.Table 2: Remuneration of key management personnel for the year ended 30 June 2018Short-TermPost- EmploymentLong- TermShare- Based PaymentTotalTotal Performance Related (%)30 June 2018($)Salary and FeesCash BonusNon-Monetary benefitsSuper annuationLong Service LeavePerformance RightsDirectorsP T Kempen73,437-1,56325,000--100,000-S A Hupert475,000--25,00018,339-518,339-A B Hall350,000--25,00010,106-385,106-R Lyle19,026--1,807--20,833-A Glenning91,324--8,676--100,000-L Farrell68,493--6,507--75,000-ExecutivesD Tauber315,528--19,4722,43353,426390,85913.7%M Westerhoff444,834173,21417,5552,698-124,500762,80139.0%B Levin284,24788,147---82,737455,13137.5%S Lambright219,645333,452---18,688571,78561.6%2,341,534594,81319,118114,16030,878279,3513,379,854Compensation options granted, vested and exercised during the prior year as part of remuneration During the reporting period, 27,347 rights with a fair value of $46,794 (TSR hurdle - $0.72, EPS hurdle - $2.37 per performance right) were granted as performance rights to Danny Tauber with a grant date of 7 September 2017 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 76,759 rights with a fair value of $131,344 (TSR hurdle - $0.72, EPS hurdle - $2.37 per performance right) were granted as performance rights to Malte Westerhoff with a grant date of 7 September 2017 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 23,324 rights with a fair value of $39,910 (TSR hurdle - $0.72, EPS hurdle - $2.37 per performance right) were granted as performance rights to Brad Levin with a grant date of 7 September 2017 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.During the reporting period, 18,023 rights with a fair value of $30,840 (TSR hurdle - $0.72, EPS hurdle - $2.37 per performance right) were granted as performance rights to Sean Lambright with a grant date of 7 September 2017 under the Current LTI Plan. The performance rights have a 4 year vesting period from grant date and are automatically exercised upon achievement of the vesting conditions.PRO MEDICUS ANNUAL REPORT 201925Table 3: Shareholdings of Key Management PersonnelOrdinary shares held in Pro Medicus Limited(Number)Balance at 1 July 2018On exercise of perfor-mance rightsNet change otherBalance at 30 June 201930 June 2019OrdinaryOrdinaryOrdinaryOrdinaryDirectors P T Kempen678,082--678,082S A Hupert29,107,660--29,107,660A B Hall29,067,500--29,067,500A Glenning4,000--4,000L Farrell2,501--2,501ExecutivesD Tauber419,49633,750(71,673)*381,573M Westerhoff121,18072,188(136,000)**57,368B Levin38,90820,625(13,750)***45,783S Lambright180,000--180,000Total59,619,327126,563(221,423)59,524,467* Danny Tauber sold 71,673 shares throughout the year at the prevailing market share price.** Malte Westerhoff sold 136,000 shares throughout the year at the prevailing market share price.*** Brad Levin sold 13,750 shares throughout the year at the prevailing market share price.Table 4: Performance rights of Key Management PersonnelPerformance rights held in Pro Medicus Limited(Number)Balance at 1 July 2018Granted as remunerationPerformance rights exercisedBalance at 30 June 2019Not yet vestedVested and exercisable at 30 June 201930 June 2019DirectorsP T Kempen------S A Hupert------A B Hall------A Glenning------L Farrell------ExecutivesD Tauber133,64715,384(33,750)115,281(115,281)-M Westerhoff310,79845,306(72,188)283,916(283,916)-B Levin121,23013,910(20,625)114,515(114,515)-S Lambright40,21110,748-50,959(50,959)-Total605,88685,348(126,563)564,671(564,671)-For personal use only26Loans to Key Management PersonnelNo loans are made to Key Management Personnel or other staff.Other transactions and balances with Key Management PersonnelPurchasesDuring the year ended 30 June 2019, lease payments of $200,000 (2018: $169,476) in respect of the Group’s operating premises at 450 Swan Street Richmond were paid to Champagne Properties Pty. Ltd., an entity controlled by S. Hupert and A. Hall. Commercial arrangements on an ‘arm’s length basis’ have been determined by an independent assessment of rental and lease terms.DIRECTORS’ MEETINGSThe numbers of meetings of Directors (including meetings of committees of Directors) held during the year and the number of meetings attended by each Director were as follows:Directors’ MeetingsEligible to attendAudit CommitteeEligible to attendNumber of meetings held:112Number of meetings attended:P. T. Kempen111122A. Glenning111122L. Farrell101112A. B. Hall111122S. A. Hupert111122Committee membershipAs at 30 June 2019, the company had an Audit Committee comprising the 3 Non-Executive Directors and 2 Executive Directors. ROUNDINGThe amounts contained in this report and in the financial report have been rounded to the nearest $1,000 (where rounding is applicable) under the option available to the Company under ASIC Corporations (Rounding in Financial/Directors Reports) instrument 2016/191. The Company is an entity to which the Class Order applies.AUDITOR INDEPENDENCE AND NON-AUDIT SERVICESThe Directors received a declaration from the auditor of Pro Medicus Limited (refer page 27).NON-AUDIT SERVICESThe following non-audit services were provided by the company’s auditor, Ernst & Young. The directors are satisfied that the provision of non-audit services is compatible with the general standard of independence for the auditors imposed by the Corporations Act. The nature and scope of the non-audit service provided means that auditor independence is not compromised.Ernst & Young received the following amount for the provision of non-audit services:Professional services rendered in respect to taxation matters $79,270Signed in accordance with a resolution of the Directors.P T KempenDirectorMelbourne, 22 August 2019 PRO MEDICUS ANNUAL REPORT 201927AUDITOR’S INDEPENDENCE DECLARATION To the Directors of Pro Medicus LimitedFor personal use only28CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEConsolidatedFOR THE YEAR ENDED 30 JUNE 2019Notes2019$’0002018$’000Restated (Note 2)Revenue from contracts with customers550,10533,872Interest revenue24456Revenue50,34933,928Cost of Sales(1,409)(220)Gross Profit48,94033,708Net foreign currency gains6(a)411463Accounting and secretarial fees(791)(678)Advertising and public relations(1,570)(1,035)Depreciation and amortisation6(b)(6,084)(4,938)Insurance(635)(737)Legal costs(368)(539)Operating lease expense (593)(531)Other expense(776)(1,060)Salaries and employee benefits expense6(b)(11,536)(8,537)Travel and accommodation(875)(815)Profit before income tax26,12315,301Income tax expense7(6,998)(5,336)Profit for the year1819,1259,965Other Comprehensive IncomeItems that may be reclassified subsequently to profit and lossForeign Currency translation(433)(63)Other comprehensive income for the year(433)(63)TOTAL COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX18,6929,902Earnings per share (cents per share)8– Basic for net profit for the year18.5¢9.7¢– Diluted for net profit for the year18.3¢9.5¢This Consolidated Statement of Comprehensive Income should be read in conjunction with the notes to the financial statements.PRO MEDICUS ANNUAL REPORT 201929CONSOLIDATED STATEMENT OF FINANCIAL POSITION ConsolidatedAS AT 30 JUNE 2019Notes2019$’0002018$’000Restated (Note 2)ASSETSCurrent AssetsCash and cash equivalents1032,31525,238Trade and other receivables1117,4194,992Accrued revenue1,7763,229Contract assets2, 5210184Inventories123154Prepayments705707Total Current Assets52,45634,404Non-current AssetsDeferred tax assets712,1316,466Plant and equipment13503352Trade and other receivables115042,351Contract assets2, 5516580Intangible assets1418,16816,854Prepayments-36Total Non-current Assets31,82226,639TOTAL ASSETS84,27861,043LIABILITIES Current LiabilitiesTrade and other payables153,4211,999Income tax payable766838Deferred revenue167,6265,032Other current financial liabilities28159193Provisions171,9501,838Total Current Liabilities 13,9229,900Non-current LiabilitiesDeferred tax liabilities75,7314,883Deferred revenue1615,28711,096Provisions175095Total Non-current Liabilities21,06816,074TOTAL LIABILITIES34,99025,974NET ASSETS49,28835,069EQUITYContributed equity181,9621,962Share buyback reserve(73)(73)Share reserve1810,2904,920Foreign currency translation reserve18(351)82Retained earnings1837,46028,178TOTAL EQUITY49,28835,069This Consolidated Statement of Financial Position should be read in conjunction with the notes to the financial statements.For personal use only30ConsolidatedFOR THE YEAR ENDED 30 JUNE 2019Issued Capital$’000Share Buyback Reserve$’000Share Reserve$’000Foreign Currency Translation Reserve$’000Retained Earnings$’000Total Equity$’000At 1 July 20171,937(73)1,71714531,10834,834Impact of adoption of new accounting standards (i)————(7,747)(7,747)Balance at 1 July 2017 (Restated Note 2)1,937(73)1,71714523,36127,087Profit for the year————9,9659,965Other comprehensive income———(63)—(63)Total comprehensive income for the period———(63)9,9659,902Transaction with owners in their capacity as ownersShare based payment——564——564Tax effect of share based payments——2,639——2,639Exercise of share options25————25Dividends————(5,150)(5,150)At 30 June 20181,962(73)4,9208228,17835,069At 1 July 20181,962(73)4,9208228,17835,069Profit for the year————19,12519,125Other comprehensive income———(433)-(433)Total comprehensive income for the period———(433)19,12518,692Transaction with owners in their capacity as ownersShare Based Payment——781——781Tax effect of share based payments——4,589——4,589Dividends————(9,843)(9,843)At 30 June 20191,962(73)10,290(351)37,46049,288(i) The Group has adopted AASB 15 Revenue from Contracts with Customers on a full retrospective basis. This resulted in a decrease of $7,747,000 to retained earnings as at 1 July 2017, being the cumulative effect on initial application of the standard (refer to Note 2).This Consolidated Statement of Changes in Equity should be read in conjunction with the notes to the financial statements.CONSOLIDATED STATEMENT OF CHANGES IN EQUITYPRO MEDICUS ANNUAL REPORT 201931CONSOLIDATED STATEMENT OF CASH FLOWSConsolidatedFOR THE YEAR ENDED 30 JUNE 2019Notes2019$’0002018$’000Cash flows from operating activitiesReceipts from customers47,76332,208Payments to suppliers and employees(15,807)(13,387)Income tax paid(7,298)(4,948)Net cash flows from operating activities1024,65813,873Cash flows from investing activitiesPayments for capitalised development costs 14(7,207)(6,164)Interest received24456Purchase of plant and equipment13(342)(219)Net cash flows used in investing activities(7,305)(6,327)Cash flows from financing activitiesPayment of dividends on ordinary shares9(9,843)(5,150)Proceeds from issuing shares—25Net cash flows used in financing activities(9,843)(5,125)Net increase in cash and cash equivalents7,5102,421Net foreign exchange differences(433)42Cash and cash equivalents at beginning of period25,23822,775Cash and cash equivalents at end of period1032,31525,238This Consolidated Statement of Cash Flows should be read in conjunction with the notes to the financial statementsFor personal use only321. CORPORATE INFORMATIONThe financial report of Pro Medicus Limited (the Company) for the year ended 30 June 2019 was authorised for issue in accordance with a resolution of Directors on 22 August 2019.Pro Medicus Limited is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.The nature of the operations and principal activities of the Group are described in the Directors’ Report.2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(a) Basis of preparation The financial report is a general-purpose financial report, which has been prepared in accordance with the requirements of the Corporations Act 2001, Australian Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards board. The financial report has also been prepared on a historical cost basis.The financial report is presented in Australian dollars and all values are rounded to the nearest thousand dollars ($000) unless otherwise stated.(b) Statement of compliance with IFRS The financial report complies with Australian Accounting Standards and International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.(c) Basis of consolidationThe consolidated financial statements comprise the financial statements of Pro Medicus Limited and its subsidiaries as at 30 June each year (the Group). Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has:• Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee)• Exposure, or rights, to variable returns from its involvement with the investee, and• The ability to use its power over the investee to affect its returns.When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:• The contractual arrangement with the other vote holders of the investee• Rights arising from other contractual arrangements• The Group’s voting rights and potential voting rightsThe Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains a control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the statement of comprehensive income from the date the Group gains control until the date the Group ceases to control the subsidiary.Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group’s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:– Derecognises the assets (including goodwill) and liabilities of the subsidiary.– Derecognises the carrying amount of any non-controlling interest.– Derecognises the cumulative translation differences, recorded in equity.– Recognises the fair value of the consideration received.– Recognises the fair value of any investment retained.– Recognises any surplus or deficit in profit or loss.– Reclassifies the parent’s share of components previously recognised in OCI to profit or loss or retained earnings, as would be required if the Group had directly disposed of the related assets or liabilities.Any contingent consideration to be transferred by the acquirer will be recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration which is deemed to be an asset or liability will be recognised in accordance with AASB 9 Financial Instruments either in profit or loss or in other comprehensive NOTES TO FINANCIAL STATEMENTSFOR THE YEAR ENDED 30 JUNE 2019PRO MEDICUS ANNUAL REPORT 201933income. If the contingent consideration is classified as equity, it shall not be remeasured.(d) New accounting standards and interpretationsThe accounting policies adopted are consistent with those of the previous financial year except the adoption of new standards effective as of 1 July 2018. The group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. (i) AASB 15 Revenue from Contracts with CustomersThe Group has adopted AASB 15 Revenue from Contracts with Customers from 1 July 2018. The Group has applied the full retrospective approach by restating the comparative period and recording the cumulative impact of the adoption in retained earnings as at 1 July 2017.The Group’s contracts with customers comprise multiple goods and services, typically with specific fixed or variable consideration receivable, including:• Installation and professional services;• Product licences;• Transactional services, including image viewing and image archiving; and• Support services, including updates and upgrades to the product licence.The Group’s contracts with customers comprise multiple activities in order to provide customers with the specified product. The nature of the Group’s products requires significant integration of various goods and services promised in contracts that represent a combined output – being the offered product. The multiple goods or services in the contract are highly interrelated and are integral in combination to the performance of the product.The Group has determined that within its contracts with customers there is one performance obligation of delivering a specified product given:• The Group provides a significant service of integrating the goods or services with other goods or services promised in the contract. The combined output – being the offered product – represents a bundle of the Group’s various goods or services;• Goods or services (i.e. installation, product licence, transaction services and support services) are highly interrelated and integral to the performance of the product. The Group could not fulfil its performance obligation of delivering a specified product by transferring each of the goods or services independently; and• Only the Group can provide product installation, transactional services and support (including significant updates/upgrades) services to customers of product licences, given the associated intellectual property of the product owned by the Group.Revenue from multi-element contracts is recognised over the term of the contract, commencing when the product is ready for use following the installation and establishment of the product licence on the basis that:• Product updates/upgrades received by the customer over the contract period are frequent and significant to the performance and compliance of the products with relevant regulatory authorities;• Customers have no alternate use for the Group’s products outside of the contract period; and• The Group has an enforceable right to payment for performance completed to date during the period of the contract.Revenue is recognised by reference to the satisfaction of the one performance obligation using the input method. The input method is applied based on the elapsed term of the contract in comparison to the length of the total contract term from when the product is ready for use by the customer until the licence and support periods end.The Group receives consideration for certain elements of product contracts that is based on transaction volumes and dependent upon customer activity. Such consideration is recognised as revenue as the customer activity occurs over the term of the contract and the Group becomes entitled to payment. Directly attributable commissions paid to employees of the Group for obtaining contracts are initially capitalised as a contract asset and recognised within salaries and employee benefits expense over time as revenue from the related contract is recognised. The carrying value of contract assets are assessed for impairment at each reporting date.Under AASB 118, the recognition of each good or service within customer contracts was predominantly separate.On the adoption of AASB 15, the determination of each contract containing a single performance obligation and satisfaction of that performance obligation over-time has resulted in an impact to the timing of revenue recognition for the following:• Installation and professional services fees that were recognised under AASB 118 based on the stage of completion of the service, measured as a percentage of the total expected services to be provided for each contract prior to the product becoming ready for use; and• Upfront licence fees for a contractual term with an unlimited transactional services element were recognised at a point in time when the product was ready for use as subsequent support provided to customers was considered a separate service.For personal use only34(A) Impact on transition to AASB 15 at 1 July 2017 applying the full retrospective method.(B) Impact of AASB 15 at 30 June 2018 and 30 June 2019, having previously applied AASB 118.Consolidated30 Jun 2019$’000(B)30 Jun 2018$’000(B)1 Jul 2017$’000(A)Current assetsContract assets210184155Total current assets210184155Non-current assetsContract assets516580590Deferred tax assets5,4513,9724,742Total non-current assets5,9674,5525,332Total Assets6,1774,7365,487Current liabilitiesDeferred revenue5,6764,0403,110Total current liabilities5,6764,0403,110Non-current liabilitiesDeferred revenue15,28711,0969,842Deferred tax liabilities184194282Total non-current liabilities15,47111,29010,124Total liabilities21,14715,33013,234Net Assets(14,970)(10,594)(7,747)EquityForeign currency translation reserve (476)(70)—Retained earnings (14,494)(10,524)(7,747)Total Equity (14,970)(10,594)(7,747)The adoption of AASB 15 has had the following impact on the Group after applying the full retrospective approach:Impact on the consolidated statement of financial position (increase/(decrease)) as at 30 June 2019:The following outlines the impact on the consolidated statement of financial position (increase / (decrease)) at the transition date on 1 July 2017, and had AASB 15 been applied at 30 June 2019 and 30 June 2018:PRO MEDICUS ANNUAL REPORT 201935(A) The impact on income tax expense for the year ended 30 June 2018 includes the deferred tax impact for a change in legislative income tax rates in the USA. The impact on basic and diluted earnings per share is, as follows:- Basic earnings per share(3.77¢) (2.69¢) - Diluted earnings per share(3.73¢) (2.69¢) There is no impact on the consolidated statement of cash flows.(ii) AASB 9 Financial InstrumentsThe Group has adopted AASB 9 Financial Instruments retrospectively from 1 July 2018, with no changes to comparatives. AASB 9 introduces new requirements for:• Classification and measurement of financial assets and financial liabilities• Impairment of financial assets• Hedge accounting Classification and measurement of financial assets and financial liabilities Under AASB 9, the Group has determined that there is no change to classification and measurement to financial assets and financial liabilities. The table below outlines the accounting treatment for financial assets and financial liabilities under AASB 139 as compared to AASB 9:Financial Asset / LiabilityPrevious AASB 139Current AASB 9Cash and cash equivalentsAmortised costAmortised costTrade and other receivablesAmortised costAmortised costForeign currency forward contractsFair value through profit or lossFair value through profit or lossConsolidated30 Jun 2019$’00030 Jun 2018$’000Revenues from contracts with customers(5,116)(2,089)Salaries and employee benefits expense10719Income tax expense (A)(1,323)709Profit for the period(3,900)(2,779)Other comprehensive incomeForeign currency translation(476)(70)Other comprehensive income for the period(476)(70)Total comprehensive income for the period(4,376)(2,849)The adoption of AASB 15 has had the following impact on the Group after applying the full retrospective approach:Impact on the consolidated statement of comprehensive income (increase/(decrease)) for the year ended 30 June 2019:The following outlines the impact on the consolidated statement of comprehensive income (increase/(decrease)) of applying AASB 15 for the year ended 30 June 2019 and 30 June 2018:For personal use only362. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d) Impairment of financial assets The adoption of AASB 9 has changed the Group’s accounting for impairment losses for trade and other receivables by replacing AASB 139’s incurred loss approach with a forward-looking expected credit loss. (“ECL”) approach. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive. The Group has applied the simplified approach to trade receivables in AASB 9 and has calculated ECLs based on lifetime expected credit losses. A provision for ECLs is determined based on historic credit loss rates and adjusted for forward looking factors specific to the debtor and the economic environment. Based on the assessment undertaken by the Group, there has been no material impact to the statement of financial position and statement of comprehensive income for the year ended 30 June 2019 and the comparative period. Hedge accounting The Group did not apply hedge accounting during the year ended 30 June 2019 and in the comparative period.3. SIGNIFICANT ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONSThe preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates on historical experience and on other various factors it believes to be reasonable under the circumstances, the result of which form the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.Management has identified the following critical accounting policies for which significant judgements, estimates and assumptions are made. Actual results may differ from these estimates under different assumptions and conditions and may materially affect financial results or the financial position reported in future periods.Further details of the nature of these assumptions and conditions may be found in the relevant notes to the financial statements.(i) Significant accounting judgements, estimates and assumptionsCapitalisation of development costs:Development costs are only capitalised by the Group when it can be demonstrated that the technical feasibility of completing the intangible asset is valid so that the asset will be available for use or sale.The capitalisation of development costs includes an overhead rate which has been estimated from total costs. The estimated development overheads rate has been calculated by dividing the development labour costs over total labour costs to give a percentage of development labour rate. The development labour rate is then applied against the total overheads of the company, to give an estimate of the amount of overheads that relates to development.Impairment of non-financial assets:The Group assesses impairment of all assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists the recoverable amount of the asset is determined. Management has tested certain assets for impairment in this financial period. Refer to Note 14 of the financial statements for significant assumptions applied in assessing for impairment on non-financial assets.Taxation:The Group’s accounting policy for taxation requires management’s judgement as to the types of arrangements considered to be a tax on income in contrast to an operating cost. Judgement is also required in assessing whether deferred tax assets and certain deferred tax liabilities are recognised on the statement of financial position. Deferred tax assets, including those arising from un-recouped tax losses, capital losses and temporary differences, are recognised only where it is considered more likely than not that they will be recovered, which is dependent on the generation of sufficient future taxable profits. Deferred tax liabilities arising from temporary differences in investments, caused principally by retained earnings held in foreign tax jurisdictions, are recognised unless repatriation of retained earnings can be controlled and are not expected to occur in the foreseeable future.Assumptions about the generation of future taxable profits and repatriation of retained earnings depend on management’s estimates of future cash flows. These depend on estimates of future sales volumes, operating costs, capital expenditure, dividends and other capital management transactions. Judgements are also required about the application of income tax legislation. These judgements and assumptions are subject to risk and uncertainty, hence there is a possibility that changes in circumstances will alter expectations, which may impact the amount of deferred tax assets and deferred tax liabilities recognised on the statement of financial position and the amount of other tax losses and temporary differences not yet recognised. In such circumstances, some or all of the carrying amounts of recognised deferred tax assets and liabilities may require adjustment, resulting in a corresponding credit or charge to the statement of comprehensive income.PRO MEDICUS ANNUAL REPORT 201937Deferred tax assets are recognised for deductible temporary differences as management considers that it is probable that future taxable profits will be available to utilise those temporary differences.Income taxes:The group is subject to income taxes in Australia and jurisdictions where it has foreign operations. Significant judgement is required in determining the worldwide provision for income taxes. There are many transactions and calculations during the ordinary course of business for which the ultimate tax determination is uncertain. The Group recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred tax provisions in the period in which such determination is made.Net investment in foreign operations:The Group maintains inter-company loans it assesses to represent a part of its net investment in its foreign operations. The judgements made in assessing these loans to represent net investments are on the basis the loans are neither planned nor likely to be settled within the foreseeable future, the loans do not include trade receivables or trade payable and the loans represent a return of funds from their investment in the respective subsidiaries.Share-based payments:The Group measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option/performance rights, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value of share-based payment transactions are disclosed in Note 19.Revenue recognitionRefer to Note 2(d)(i) for significant judgements with respect to revenue recognition.4. OPERATING SEGMENTSThe Group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team (the chief operating decision makers) in assessing performance and in determining the allocation of resources.The operating segments are identified by management based on country of origin. Discrete financial information is reported to the executive management team on at least a monthly basis.Impairment is not monitored at segment level.Types of products and servicesThe Group produces integrated software applications for the health care industry. In addition, the Group provides services in the form of installation and support.Accounting policies and inter-segment transactionsAn operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start-up operations which are yet to earn revenues.Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the Board of Directors.Operating segments have been identified based on the information provided to the chief operating decision makers – being the executive management team.The Group aggregates two or more operating segments when they have similar economic characteristics and the segments are similar in each of the following respects:• Nature of the products and services• Type or class of customer for the products and services• Nature of the regulatory environmentOperating segments that meet the quantitative criteria as prescribed by AASB 8 are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where information about the segment would be useful to users of the financial statements.Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”.Inter-entity sales are recognised based on an internally set transfer price. The price aims to reflect what the business operation could achieve if they sold their output and services to external parties at arm’s length.For personal use only38Operating SegmentsAustraliaEuropeNorth AmericaTotal Operations2019 $’0002018 $’000(Restated)2019 $’0002018 $’000(Restated)2019 $’0002018 $’000(Restated)2019 $’0002018 $’000(Restated)RevenueSales to external customers - software9,1827,0515,3062,62334,41224,19848,90033,872Sales to external customers - hardware——1,205———1,205—Inter-segment sales31,92320,6917,1897,451——39,11228,142Total segment revenue41,10527,74213,70010,07434,41224,19889,21762,014Inter-segment elimination(39,112)(28,142)Total consolidation revenue50,10533,872ResultsSegment result22,02713,5572,9591,05889363025,87915,245Interest revenue24456Non segment expensesIncome tax expense(6,998)(5,336)Net profit19,1259,965AssetsNon-current assets 22,54321,0101191206143,02023,27624,150Deferred tax asset7,2112,9621462424,7743,26212,1316,466Current assets16,66423,83016,69713,22122,86410,75956,22547,810Segment assets46,41847,80216,96213,58328,25217,04191,63278,426Inter-segment elimination(7,354)(17,383)Total assets84,27861,043LiabilitiesSegment liabilities2,14115,4283,3602,39638,57823,82044,07941,644Inter-segment elimination(9,089)(15,670)Total liabilities34,99025,974Other segment informationCapital expenditure7,4206,235616469847,5506,383Depreciation and amortisation5,9624,823626560506,0844,938Cash flow informationNet cash flow from operating activities6683,097(1,111)(3,050)25,10113,82624,65813,873Net cash flow from investing activities(7,175)(6,179)(61)(64)(69)(84)(7,305)(6,327)Net cash flow from financing activities(9,843)(5,125)————(9,843)(5,125)PRO MEDICUS ANNUAL REPORT 2019395. REVENUE FROM CONTRACTS WITH CUSTOMERSSet out below is the disaggregation of the Group’s revenue from contracts with customers:Revenue from multi-element contracts is recognised over the term of the contract, commencing when the product is ready for use following the installation and establishment of the product licence.Revenue received in advance of the commencement of the term of the contract is initially deferred as contract liabilities (refer to Note 16). Some contracts contain minimum annual volume amounts for transactional services that are recognised as revenue in advance of billing and disclosed as accrued revenue. During the year ended 30 June 2019, the Group entered into a bespoke contract to provide a certain customer with a perpetual licence to use a product, irrespective of the customer’s transactional activity. Support services are sold to the customer, at the customer’s discretion, in separate short-term contracts. The pricing for these support services contracts are at normal commercial terms. Directly attributable commissions paid to employees of the Group for obtaining contracts are initially capitalised as a contract asset and recognised within salaries and employee benefits expense over time as revenue from the related contract is recognised.ConsolidatedYear ended 30 June 2019 ($’000)AustraliaEuropeNorthAmericaTotalTypes of goods and servicesRadiology Information System (RIS) 8,080 — — 8,080 Picture Archiving Communications System (Visage 7/Open Archive) 1,102 6,482 34,412 41,996 Other— 29 — 29 Total revenue per statement of comprehensive income 9,182 6,511 34,412 50,105 Timing of revenue recognitionPoint in time—4,255—4,255 Over time 9,182 2,256 34,412 45,850 Total revenue per statement of comprehensive income9,1826,51134,41250,105ConsolidatedYear ended 30 June 2018 (Restated) ($’000) AustraliaEuropeNorthAmericaTotalTypes of goods and servicesRadiology Information System (RIS) 6,029 — — 6,029 Picture Archiving Communications System (Visage 7/Open Archive) 1,022 2,583 24,198 27,803 Other— 40 — 40 Total revenue per statement of comprehensive income 7,051 2,623 24,198 33,872 Timing of revenue recognitionPoint in time————Over time 7,051 2,623 24,198 33,872 Total revenue per statement of comprehensive income 7,051 2,623 24,198 33,872 For personal use only406. INCOME AND EXPENSES(a) Net foreign currency gains/(losses)ConsolidatedNotes2019$’0002018$’000(Restated)Currency gains3,3873,959Currency (loss)(2,817)(3,303)Fair value loss on financial instruments – forward exchange contracts(159)(193)Total net foreign currency gains411463(b) ExpensesDepreciation and amortisationProperty improvements1333Motor vehicles1377Office equipment13169122Furniture and fittings131218Capitalised development costs145,8934,788Computer software14——Total depreciation and amortisation expense 6,0844,938Salaries and employee benefits expenseGross wages and salaries15,19711,971Capitalised wages and salaries**(5,624)(5,026)Long service leave provision8063Share-based payment ***781564Defined contribution plan1,102965Total salaries and employee benefits expense11,5368,537**The Group’s total wages and salaries incurred was $15,197,000 (2018: $11,971,000 restated) of which $5,624,000 (2018: $5,026,000) of these costs have been capitalised as development costs within intangible assets.***241,250 performance rights were granted on 16 August 2018 under the Group’s long-term incentive plan. The performance rights vest in accordance with performance conditions related to earnings per share (“EPS”) and total shareholder returns (“TSR”) after completion of a service condition being 4 years from the grant date. The fair value of the performance rights at grant date were TSR hurdle - $1.10 and EPS hurdle - $4.24 per performance. The amount of share-based payment expense for the year ended 30 June 2019 takes into consideration the probability of certain performance conditions vesting.Consolidated2019$’0002018$’000Restated Amounts included in deferred revenue at the beginning of the year5,0324,035Set out below is the amount of salaries and employee benefits expense recognised from:Consolidated2019$’0002018$’000Restated Amounts included in contract assets at the beginning of the year184155Revenue from major customersIncluded in the North American segment are customers that contributed to the total consolidated Group revenue by 13.8% (2018: 17.3% restated) from one party and nil (2018: 12.4% restated) from another party. No other customer contributed 10% or more to the Group’s revenue for the year ended 30 June 2019.5. REVENUE FROM CONTRACTS WITH CUSTOMERS (cont’d)Set out below is the amount of revenue from contracts with customers recognised from:PRO MEDICUS ANNUAL REPORT 2019417. INCOME TAX Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date.Deferred income tax is provided on all temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.Deferred income tax liabilities are recognised for all taxable temporary differences, except: • where the deferred income tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.• when the taxable temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, and the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.Deferred income tax assets are recognised for all deductible temporary differences, carry forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax assets and unused tax losses can be utilised, except:• where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.• when the deductible temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, in which case a deferred tax asset is only recognised to the extent that it is probable that the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilised.The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.Unrecognised deferred income tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on the tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.Income taxes relating to items recognised directly in equity are recognised in equity and not in the statement of comprehensive income.Unrecognised temporary differencesAt 30 June 2019, there are no temporary differences associated with the Group’s investments in subsidiaries being recognised as the parent is able to control the timing of the reversal of any temporary differences and it is not probable any temporary difference will reverse in the foreseeable future.Tax consolidation legislationPro Medicus Limited and its wholly-owned Australian controlled entities implemented the tax consolidation legislation as of 1 July 2009. Members of the tax consolidated group have entered into a tax funding agreement.The head entity, Pro Medicus Limited, and the controlled entities in the tax consolidated group continue to account for their own current and deferred tax amounts under the tax funding agreement. The Group applies the Group allocation approach to determining the appropriate amount of current taxes and deferred taxes to allocate to members of the tax consolidated group. An allocation of income tax liabilities between the entities of the tax consolidated group will be made should the head entity default on its tax payment obligations. No such amounts have been recognised in the financial statements on the basis that the possibility of default is remote.In addition to its own current and deferred tax amounts, Pro Medicus Limited also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group.For personal use only427. INCOME TAX (cont’d)ConsolidatedNotes2019$’0002018$’000The major components of income tax expense are:Statement of Comprehensive IncomeCurrent income taxCurrent income tax charge8,5765,126Prior year adjustment(659)(1)Deferred income taxRelating to origination and reversal of temporary differences(919)211Income tax expense reported in profit or loss6,9985,336Statement of Changes of EquityCurrent income taxImpact of the Employee Share Trust – vested share based payments(691)(1,283)Deferred income taxRelating to origination and reversal of temporary differences due to the Employee Share Trust – unvested share-based payments(3,898)(1,356)Income tax benefit reported directly in the statement of changes in equity(4,589)(2,639)A reconciliation between tax expense and the product of accounting profit before income tax multiplied by the Group’s applicable income tax rate is as follows:Accounting profit before tax26,12315,301At the applicable statutory income tax rate in each country – Australia6,6814,065– United States of America226161– Germany892297Prior year adjustment(659)(1)Expenditure not allowable for income tax purposes(267)(503)Benefit from vested share based payments(61)(171)Impact of change in USA income tax rates on deferred tax balances—1,351Other 186137Income tax expense reported in profit or loss6,9985,336PRO MEDICUS ANNUAL REPORT 2019437. INCOME TAX (cont’d)8. EARNINGS PER SHAREBasic earnings per share is calculated as net profit attributable to members of the Group, adjusted to exclude any costs of servicing equity (other than dividends) divided by the weighted average number of ordinary shares, adjusted for any bonus element.Diluted earnings per share is calculated as net profit attributable to members of the Group adjusted for: • Costs of servicing equity (other than dividends)• The after tax effect of dividends and interest associated with dilutive potential ordinary shares that have been recognised as expenses• Other non-discretionary changes in revenue or expenses during the period that would result from the dilution of potential ordinary shares • Dilutive potential ordinary shares adjusted for any bonus elementand then divided by the weighted average number of ordinary shares.Deferred income taxConsolidated Statement of Financial PositionConsolidated Statement of Comprehensive IncomeDirect to EquityDeferred income tax at 30 June relates to the following:2019 $’0002018 $’000(Restated)2019 $’0002018 $’0002019 $’0002018 $’000Deferred Tax liabilitiesForeign currency exchange gain5112069612——Capitalised development expenses5,4394,525(914)(261)——Depreciation expenses5744(13)5——Contract assets1841941088——Deferred tax liabilities5,7314,883(848)444——Deferred tax assetsEmployee entitlements619466153(224)——Intellectual property expenses271290(19)(18)——Accruals372017(2)——Deferred revenue5,4513,9721,479(770)——Employee Share Trust – unvested share based payments5,7491,7151363593,8981,356Other 431———Deferred tax assets12,1316,4661,767(655)3,8981,356Deferred tax movement (charged) or credited to profit or loss919(211)——Deferred tax movement (charged) or credited directly to equity——3,8981,356For personal use only44Consolidated2019$2018 (Restated)$Net profit attributable to ordinary equity holders19,125,3989,964,880NumberNumberWeighted average number of ordinary shares for basic earnings per share103,574,482103,190,471Effect of dilution:Share options—17,534Performance rights853,0101,083,201Weighted average number of ordinary shares adjusted for the effect of dilution104,427,492104,291,206There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these financial statements9. DIVIDENDS PAID AND PROPOSEDConsolidatedDeclared and paid during the year:2019$’0002018$’000Dividends on ordinary sharesFinal franked dividend for 2018: 3.5 cents (2017: 2.5 cents franked)3,6262,566Interim franked dividend for 2019: 3.5 cents (2018: 2.5 cents unfranked)3,6272,584Advance final franked dividend for 2019: 2.5 cents (2018: nil)2,590—9,8435,150Proposed for approval by directors (not recognised as a liability as at 30 June):Dividends on ordinary shares:Final franked dividend for 2019: 4.5 cents (2018: 3.5 cents franked)4,6633,618Total dividends proposed4,6633,618Franking credit balance −franking account balance as at the end of the financial year at 30% (2018: 30%)2,417820 −franking credits that will arise from the payment of income tax payable as at the end of the financial year434954 −franking debits that will arise from the payment of dividends as at the end of the financial year—— −franking credits that the entity may be prevented from distributing in the subsequent financial year—— −prior period adjustment——2,8511,774The amount of franking credits available for future reporting periods: −impact on the franking account of dividends proposed or declared before the financial report was authorised for issue but not recognised as a distribution to equity holders during the period(1,998)(1,372)853402The tax rate at which paid dividends have been franked is between 27.5% and 30% (2018: 30%). Dividends proposed will be fully franked. The following reflects the income and share data used in the basic and diluted earnings per share computations:PRO MEDICUS ANNUAL REPORT 20194510. CASH AND CASH EQUIVALENTSConsolidated2019$’0002018$’000Cash at bank and in hand *24,31511,228Short-term deposits8,00014,01032,31525,238*$450,000 (2018: $300,000) of the cash at bank balance is held as a deposit for foreign exchange forward contracts. The deposit matures and becomes available following the settlement of the foreign exchange forward contracts within three months of the reporting date.Cash and cash equivalents in the Statement of Financial Position and Statement of Cash Flow comprise cash at bank and in hand and short term deposits with an original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes of value.Cash at bank earns interest at floating rates based on daily bank deposit rates.Short term deposits are made for varying periods of between 30 days and 90 days, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates.The fair value of cash and cash equivalents is their carrying value.Reconciliation of net profit after tax to net cash flows from operations2019$’0002018$’000Net profit 19,1259,965Adjustments for:Depreciation of property, plant and equipment191150Amortisation of intangible assets5,8934,788Interest received classified in investing activities(244)(56)Current income tax impact of vested share-based payments recognised directly in equity6911,283Fair value loss on financial instruments(34)193Share-based payment expense781564Changes in assets and liabilities(Increase)/decrease in trade and other receivables(10,580)(3,854)(Increase)/decrease in inventory23-(Increase)/decrease in deferred tax asset(1,768)(115)(Increase)/decrease in prepayments3897(Increase)/decrease in accrued revenue1,45335(Increase)/decrease in contract assets38(19)(Decrease)/increase in trade and other payables1,4231,059(Decrease)/increase in income tax payable(72)(1,134)(Decrease)/increase in deferred income6,7851,324(Decrease)/increase in deferred tax liability848(443)(Decrease)/increase in employee entitlements6736Net cash flow from operations24,65813,873 ConsolidatedFor personal use only4611. TRADE AND OTHER RECEIVABLESTrade and other receivables are recognised initially at fair value and subsequently measured at amortised cost less an allowance for any impairment.Consolidated2019$’0002018$’000CurrentTrade receivables17,8614,790Less: Allowance for expected credit losses (647)—17,2144,790Other receivables20520217,4194,992Non-currentTrade receivables5042,3515042,351Consolidated2019$’0002018$’000a) Allowance for impairment lossMovements in the provision for impairment loss were as follows:At 1 July——Charge to/(write back of) provision for the year647—Utilised during the year——Foreign exchange translation——At 30 June647—The charge to the allowance for expected credit losses during the year ended 30 June 2019 reflects a change in expected losses for a specific debtor arising during the year that did not exist in the prior year or at date of transition to AASB 9.ConsolidatedTrade receivablesAllowance for expected credit losses2019$’0002018$’0002019$’0002018$’0000 – 30 days9,9935,862——31 – 60 days1,582359——61 – 90 days1,367254——91+ days5,423666(647)—Total trade receivables18,3657,141(647)—Fair value approximates carrying value due to the short term nature of receivables. Following the adoption of AASB 9 Financial Instruments from 1 July 2019, a provision for impairment is made based on applying a simplified approach in calculating the expected credit losses (“ECL”) for debtors and other receivables (including accrued revenue). Therefore, the Group does not track changes in credit risk, but instead recognises an ECL allowance based on lifetime ECL at each reporting date. The Group’s provisioning methodology is based on its historical credit loss experience, adjusted for forward-looking factors specific to individual debtors and the economic environment. Debtors and other receivables (including accrued revenue) are written off when there is no reasonable expectation of recovering the contractual cash flows. As permitted by AASB 9, comparatives have not been restated. In the prior year, the impairment of trade receivables was assessed based on the incurred loss model and a provision raised when there was objective evidence that the Group will not be able to collect its debts. PRO MEDICUS ANNUAL REPORT 201947The allowance for expected credit losses at 30 June 2019 relates to a certain debtor. Further Information about the credit risk exposure on the Group’s other trade receivables using the provisioning methodology have not been disclosed due to the immaterial amount of expected credit losses as at 30 June 2019.Payment terms on $4,434,798 (2018: $3,499,656) of trade receivables have pre-contracted extended trading terms. Of the $4,434,798, an amount of $503,654 is due after 12 months and the remainder within 12 months.12. INVENTORYConsolidated2019$’0002018$’000Finished goods (at lower of cost and net realisable value)3154Inventory write downs recognised as an expense during the year ended 30 June 2019 total nil (2018: nil)Inventories are valued at the lower of cost and net realisable value. The cost of finished goods represents the purchase cost.Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.13. PLANT & EQUIPMENTPlant and equipment is stated at cost less accumulated depreciation and any impairment in value.Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows: 20192018Property Improvements2 to 7 years2 to 7 yearsMotor Vehicles4 to 5 years4 to 5 yearsOffice Equipment2 to 7 years2 to 7 yearsFurniture and Fittings5 years5 yearsResearch and Development Equipment3 to 4 years3 to 4 yearsAn item of plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset.Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the statement of comprehensive income in the period the item is derecognised.ImpairmentThe carrying values of plant and equipment are reviewed for impairment at each reporting date, with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired.For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.If any such indication exists and where the carrying values exceed the estimated recoverable amount, the assets or cash-generating units are written down to their recoverable amount.The recoverable amount of plant and equipment is the greater of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.For personal use only4814. INTANGIBLE ASSETSIntangible assets acquired separately are initially measured at cost. The cost of an intangible asset acquired in a business combination is its fair value as at date of acquisition. Following initial recognition, intangible assets with a finite life are carried at cost less any accumulated amortisation and any accumulated impairment losses.Amortisation is calculated on a straight-line basis over the estimated useful life of the asset. Intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the period in which the expenditure is incurred.Intangible assets are tested for impairment where an indicator of impairment exists, either individually or at the cash generating unit level. The recoverable amount is estimated and an impairment loss is recognised to the extent that the recoverable amount is lower than the carrying value.The amortisation period and method is renewed at each financial year end and adjustments, where applicable, are made on a prospective basis. Research and development costsResearch costs are expensed as incurred.An intangible asset arising from development expenditure on an internal project is recognised only when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for sale or use, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. Following initial recognition of the development expenditure, the cost model is applied requiring the asset be carried at cost less any accumulated amortisation and accumulated impairment losses. Any expenditure so capitalised 13. PLANT & EQUIPMENT (cont’d)ConsolidatedPropertyImprovementsMotorVehiclesOfficeEquipmentFurniture &FittingsResearch &DevelopmentEquipmentTotal$’000$’000$’000$’000$’000$’000Year ended 30 June 2019At 1 July 2018 net of accumulated depreciation142729219—352Additions——3305—335Disposals——————Exchange differences——8(1)—7Depreciation charge for the year(3)(7)(169)(12)—(191)At 30 June 2019 net of accumulated depreciation112046111—503At 30 June 2019Cost3344882,8724202094,323Accumulated depreciation and impairment(323)(468)(2,411)(409)(209)(3,820)Net carrying amount112046111—503Year ended 30 June 2018At 1 July 2017 net of accumulated depreciation173419636—283Additions——211——211Disposals—————Exchange differences——71—8Depreciation charge for the year(3)(7)(122)(18)—(150)At 30 June 2018 net of accumulated depreciation142729219—352At 30 June 2018Cost3334882,2044092093,919Accumulated depreciation and impairment(319)(461)(2,188)(390)(209)(3,567)Net carrying amount142729219—352PRO MEDICUS ANNUAL REPORT 201949ConsolidatedIntellectualPropertyi)DevelopmentCosts ii)SoftwareLicenses iii)Total$’000$’000$’000$’000Year ended 30 June 2019At 1 July 2018 net of accumulatedamortisation and impairment—16,853116,854Additions – internal development—7,207—7,207Disposals————Exchange differences————Amortisation charge for the year—(5,893)—(5,893)At 30 June 2019 net of accumulated amortisation and impairment—18,167118,168At 30 June 2019Cost1,84846,87932149,048Accumulated amortisation and impairment(1,848)(28,712)(320)(30,880)Net carrying amount—18,167118,168Year ended 30 June 2018At 1 July 2017 net of accumulated amortisation and impairment—15,477115,478Additions – internal development—6,164—6,164Disposals————Exchange differences————Amortisation charge for the year—(4,788)—(4,788)At 30 June 2018 net of accumulated amortisation and impairment—16,853116,854At 30 June 2018Cost1,84839,67331241,833Accumulated amortisation and impairment(1,848)(22,820)(311)(24,979)Net carrying amount—16,853116,854is amortised on a straight line basis over the period of expected benefit from the related project (5 years).Development expenditure includes costs of materials and services and salaries and wages and other employee related costs arising from the generation of the intangible asset.The carrying value of an intangible asset arising from development expenditure is tested for impairment annually when the asset is not yet available for use or more frequently when an indication of impairment arises during the reporting period.Intellectual Property – SoftwareThree separately identifiable intangible assets, in the form of software intellectual property, have previously been identified in the business acquisition of Visage Imaging:• Visage PACS• Visage MagicWeb and • AmiraFollowing initial recognition, Intellectual property is measured at cost less any accumulated amortisation. A useful life of 5 years has been determined.Software LicensesThe Group identified a separate intangible asset in the form of software licenses, in the business acquisition of Visage Imaging.Following initial recognition, software licenses are measured at cost less any accumulated amortisation. A useful life of 4 years has been determined.Customer ListThe Group identified a separate intangible asset in the form of a customer list, in the business acquisition of Visage Imaging.Following initial recognition, the customer list is measured at cost less any accumulated amortisation. A useful life of 4 years has been determined.For personal use only50i) Intellectual property was acquired through previous business combinations and is carried at cost less accumulated amortisation. These intangible assets have been assessed as having a finite life and have been fully amortised using the straight-line method over a period of 5 years.ii) Development costs have been capitalised. This intangible asset has been assessed as having a finite life and is amortised using the straight-line method over a period of 5 years. As at 30 June 2019 the carrying values of capitalised development costs are Visage PACS ($12,225,803) RIS ($5,550,439) and Visage MagicWeb ($391,236), all sit within the Australian operating segment.ImpairmentThe carrying values of intangible assets are reviewed for impairment at each reporting date, with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired.If any such indication exists and where the carrying values exceed the estimated recoverable amount, the intangible assets or cash-generating units are written down to their recoverable amount.The recoverable amount of intangible assets is the greater of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.No impairment loss was recognised during the year ended 30 June 2019 (2018: nil impairment loss).15. TRADE AND OTHER PAYABLES Trade payables and other payables are carried at amortised cost and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services.Consolidated2019$’0002018$’000(Restated)CurrentTrade payables705565Other payables and accruals2,7161,4343,4211,999(i) Trade payables are non-interest bearing and are normally settled on 30-day terms.(ii) Other payables are non-interest bearing and have an average term of 30 days.Fair value approximates carrying value due to the short-term nature of trade and other payables.16. DEFERRED REVENUEConsolidated2019$’0002018$’000(Restated)CurrentDeferred revenue from contracts with customers7,6265,0327,6265,032Non-currentDeferred revenue from contracts with customers15,28711,09615,28711,096Unsatisfied performance obligationsThe aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as at 30 June 2019 was $22,913,000 (2018: $16,128,000) and is expected to be recognised as revenue in future reporting periods as follows:Consolidated2019$’0002018$’000(Restated)Less than one year7,6265,032Between one year and seven years 15,28711,096Revenue to be recognised from unsatisfied performance obligations22,91316,128PRO MEDICUS ANNUAL REPORT 20195117. PROVISIONSProvisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are measured at the present value of management’s best estimate of the expenditure required to settle the present obligation at the reporting date.When the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.Employee leave benefitsProvision is made for employee entitlement benefits accumulated as a result of employees rendering services up to the reporting date.(i) Annual leave and sick leaveThe liability for annual leave is recognised and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date, using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currencies that match, as closely as possible the estimated future cash outflows. Expenses for non-accumulating sick leave are recognised when the leave is taken and are measured at the rates paid.(ii) Long service leaveThe liability for long service leave is recognised and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date, using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currencies that match, as closely as possible the estimated future cash outflows.Consolidated2019$’0002018$’000CurrentLong service leave989865Annual leave9619731,9501,838Non Current5095Long service leave509518. CONTRIBUTED EQUITY AND RESERVESOrdinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.ConsolidatedContributed Equity2019$’0002018$’000(i) Ordinary shares1,9621,962Issued and fully paid1,9621,962Fully paid ordinary shares carry one vote per share and carry the right to dividendsFor personal use only52(ii) Movements in shares on issueNumber of Shares2019$’000At 1 July 2018103,369,0491,962Issued for cash on exercise of options——Vesting of performance rights247,469—At 30 June 2019103,616,5181,962Number of Shares2018 $’000At 1 July 2017102,660,5491,937Issued for cash on exercise of options25,00025Vesting of performance rights683,500—At 30 June 2018103,369,0491,962Consolidated2019$’0002018$’000Share Reserve (i)Balance at 1 July 4,9201,717Performance rights expensed781564Income tax effect of the Employee Share Trust4,5892,639Balance at 30 June 10,2904,920Foreign Currency Translation Reserve (ii)Balance at 1 July82145Foreign currency movement(433)(63)Balance at 30 June (351)82Retained EarningsBalance at 1 July 28,17831,108Impact of adoption of new accounting standards at 1 July 2017—(7,746)Net profit for the year19,1259,965Dividends(9,843)(5,149)Balance at 30 June 37,46028,178(i) Share reserveThe share reserve is used to record the value of share based payments provided to employees, including KMP, as part of their remuneration. Refer to Note 19 for further details of these plans.(ii) Foreign currency translation reserveThe foreign currency translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign subsidiaries and for exchange differences arising from long term loan accounts resulting from net investment in subsidiaries.Capital ManagementWhen managing capital, management’s objective is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.Management review the capital structure to take advantage of favourable costs of capital or high returns on assets. As the market is constantly changing, management may change the amount of dividends to be paid to shareholders, return capital to shareholders, or issue new shares.During the year, the company paid dividends of $9,843,585 (2018: $5,150,121). 19. SHARE BASED PAYMENTS (i) Equity settled transactions:The Group provides benefits to its employees (including KMP) in the form of share-based PRO MEDICUS ANNUAL REPORT 201953payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).There are currently two plans in place to provide these benefits:• The Employee Share Option Plan (ESOP), which provides benefits to directors, senior executives and other employees.• The Long-Term Incentive Plan (LTIP), which provides benefits to senior executives and other employees.The cost of these equity-settled transactions with employees (for awards granted after 7 November 2002 that were unvested at 1 January 2005) is measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using either a Black Scholes model or Monte Carlo simulation model.In valuing equity-settled transactions, no account is taken of any vesting conditions, other than conditions linked to the price of the shares of Pro Medicus Limited (market conditions) if applicable.The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date).At each subsequent reporting date until vesting, the cumulative charge to the profit or loss is the product of:(i) The grant date fair value of the award;(ii) For options with non-market vesting conditions, the current best estimate of the number of awards that will vest, taking into account such factors as the likelihood of employee turnover during the vesting period and the likelihood of non-market performance conditions being met; and(iii) The expired portion of the vesting period.The charge to the statement of comprehensive income for the period is the cumulative amount as calculated above less the amounts already charged in previous periods. There is a corresponding entry to equity.Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards vest than were originally anticipated to do so. Any award subject to a market condition is considered to vest irrespective of whether or not that market condition is fulfilled, provided that all other conditions are satisfied.If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. An additional expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share (see Note 8).Employee Share Option Scheme900,000 shares were granted as options to key Visage Imaging GmbH employees under a separate agreement. The options had a grant date of 1 April 2010 and an exercise price of $1.00. The fair value of the options at grant date was $67,278 ($0.07 per option). The options had a first exercise date of 1 April 2011 and can be exercised at anytime through to expiry date of 1 April 2020. The options vest over a 5 year period on completion of service. During the reporting period, all options had vested and were fully exercised in previous reporting periods. There are no outstanding options at 30 June 2019. Information with respect to the number of options granted under the employee share option scheme is as follows:20192018Number of OptionsWeighted average exercise priceNumber of OptionsWeighted average exercise priceOutstanding at the beginning of the year——25,000$1.00— granted————— forfeited————— exercised——(25,000)$1.00— expired————Outstanding at the end of the year————Exercisable at end of year————All options above have been recognised in accordance with AASB 2 as the options were granted after 7 November 2002.For personal use only5419. SHARE BASED PAYMENTS (cont’d)Weighted average remaining contractual life The weighted average remaining contractual life for share options outstanding at 30 June 2019 is zero years (2018: zero years) Range of exercise price The range of exercise prices for options outstanding at the end of the year was nil (2018: nil).Weighted average fair valueThe weighted average fair value of options granted during the year was nil (2018: nil). Option pricing modelThe fair value of the equity-settled share options granted is estimated as at the date of the grant using a Black Scholes Model taking into account the terms and conditions upon which the options were granted.Performance RightsFormer Long Term Incentive (LTI) SchemeA long term incentive plan was established on 18 November 2011 whereby Senior Executives of the Group were offered performance rights over the ordinary shares of Pro Medicus Limited. The performance rights, issued for nil consideration, are offered for a 5 year period and vest 4 years after granting date on completion of service. The performance rights cannot be transferred and will not be quoted on the ASX. This long term incentive plan includes performance hurdles related to the Company and vesting conditions relating to the employee’s period of service. Current Long Term Incentive (LTI) SchemeA new long term incentive plan was established during 2016-17 whereby Senior Executives of the Group were offered performance rights over the ordinary shares of Pro Medicus Limited. The performance rights, issued for nil consideration, are offered for a 12 month period and vest 4 years after granting date on completion of service. The performance rights cannot be transferred and will not be quoted on the ASX. This long term incentive plan includes performance hurdles related to the Company and vesting conditions relating to the employee’s period of service. During the reporting period, 241,250 performance rights have been granted with a grant date of 16 August 2018. The performance rights vest over 4 years from grant date on completion of service. The fair value of these 241,250 performance rights at grant date was $719,551 (TSR hurdle - $1.10, EPS hurdle - $4.24 per performance right). 330,021 performance rights were granted in prior periods in relation to the 2017-18 financial performance. The performance rights vest over 4 years from grant date on completion of service. The fair value of these 330,021 performance rights at grant date was $564,707 (TSR hurdle - $0.72, EPS hurdle - $2.37 per performance right). 320,492 performance rights were granted in prior periods in relation to the 2016-17 financial performance. 90,000 performance rights from Tranche 1 vest over 4 years from grant date on completion of service. The fair value of these 90,000 performance rights at grant date was $439,326 ($4.88 per performance right). A further 180,492 performance rights from Tranche 2 vest over 4 years from grant date on completion of service. The fair value of these 180,492 performance rights at grant date was $326,003 (TSR hurdle - $0.85, EPS hurdle - $2.45 per performance right). The remaining 50,000 performance rights vest in September 2017 and the fair value of these rights was $44,500 ($0.89 per performance right). 414,375 performance rights were granted in prior periods in relation to the 2015-16 financial performance. 364,375 performance rights vest over 4 years from grant date on completion of service. The fair value of the 364,375 performance rights at grant date was $721,463 ($1.98 per performance right). The remaining 50,000 performance rights vest in September 2016 and the fair value of these rights was $44,500 ($0.89 per performance right). 397,469 performance rights were granted in prior periods in relation to the 2014-15 financial performance. 247,469 performance rights vest over 4 years from grant date on completion of service. The fair value of the 247,469 performance rights at grant date was $205,166 ($0.83 per performance right). The remaining 150,000 performance rights vest in September 2015 and the fair value of these rights was $133,737 ($0.89 per performance right). PRO MEDICUS ANNUAL REPORT 201955Information with respect to the number of performance rights granted under the long term incentive scheme is as follows:20192018Number of Performance RightsNumber of Performance RightsOutstanding at the beginning of the year1,206,6091,565,836 −granted241,250330,021 −forfeited—— −exercised(247,469)(683,500) −expired—(5,748)Outstanding at the end of the year1,200,3901,206,609Exercisable at end of year——Weighted average remaining contractual life The weighted average remaining contractual life for performance rights at 30 June 2019 is 2.4 years (2018: 2.6 years) Performance rights pricing model (Former Long Term Incentive Scheme)The fair value of the equity-settled performance rights granted under the former long term incentive scheme is estimated as at the date of the grant using a Black Scholes Model taking into account the terms and conditions upon which the performance rights were granted.There were no rights granted under the former long term incentive scheme during the period.Performance rights pricing model (Current Long Term Incentive Scheme)The fair value of the equity-settled performance rights granted for the current long term incentive scheme is estimated as at the date of the grant using Black Sholes and Monte Carlo Simulation Models taking into account the terms and conditions upon which the performance rights were granted.The following table lists the inputs to the models used:20192018Dividend yield0.69%0.82%Expected volatility14.96%15.56%Risk-free interest rate3.30%3.30%Expected life of performance rights4 years4 yearsPerformance rights exercise price$0.00$0.00Fair value of performance rights at measurement date (per performance right)$1.10-4.24$0.72-2.3720. COMMITMENTSLeasesThe determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset.Operating lease commitments – Group as lesseeLeases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases.Operating lease payments are recognised as an expense in the statement of comprehensive income on a straight-line basis over the lease term.The US operations have entered into a commercial property lease for office premises from 1 December 2015 for a 5 year period. The German operations have entered into a commercial property lease for office premises and can give notice to vacate 6 months prior to 31 March each year, whereby they sign into another 12 months.The German operations also have several motor vehicle leases which expire at various stages between July 2020 and May 2022For personal use only56Consolidated2019$’0002018$’000Future minimum rentals payable under non-cancellable operating lease as at 30 June are as follows: −Within one year364380 −After one year and not more than five years134343 −After more than five years——49872321. EVENTS AFTER THE BALANCE SHEET DATEOn 22 August 2019, the directors of Pro Medicus Limited declared a final dividend on ordinary shares in respect of the 2019 financial year. This dividend comprises a normal dividend of 4.5 cents per share. The total amount of the dividend is $4,662,743 which represents a franked dividend of a total of 4.5 cents per share. The dividend has not been provided for in the 30 June 2019 financial statements.22. AUDITOR’S REMUNERATIONConsolidated20192018Amounts received or due and receivable by Ernst & Young (Australia) for:– an audit or review of the financial report of the Company and any other entity in the Group187,200197,757– other services in relation to the Company or Group64,45096,133251,650293,890Amounts received or due and receivable by related practices of Ernst & Young (Australia):– audit of the financial report of Visage Imaging GmbH73,63287,411– other services in relation to Visage Imaging GmbH14,82027,753340,102409,05423. KEY MANAGEMENT PERSONNEL(a) Compensation for key management personnelConsolidated20192018Short-term employee benefits3,478,7772,955,465Post-employment benefits114,769114,160Other long-term benefits25,39230,878Share-based payment507,643279,351Total compensation4,126,5813,379,854(b) Loans to Key Management PersonnelNo loans are made to Key Management Personnel or staff.(c) Other transactions and balances with Key Management PersonnelPurchasesDuring the year lease payments of $200,000 (2018: $169,476) in respect of the Group’s operating premises at 450 Swan Street, Richmond were paid to Champagne Properties Pty. Ltd., an entity controlled by S. Hupert and A. Hall. Commercial arrangements on an ‘arm’s length basis’ have been determined by an independent assessment of rental and lease terms. The current arrangement is on a month to month basis.PRO MEDICUS ANNUAL REPORT 20195724. RELATED PARTY DISCLOSURE(a) SubsidiariesThe consolidated financial statements include the financial statements of Pro Medicus Limited and the subsidiaries listed in the following table.% Equity interestInvestment $000NameCountry of incorporation2019201820192018Promed (USA) Pty LtdAustralia100100——PME IP Australia Pty LtdAustralia100100——Visage Imaging (Aust) Pty LtdAustralia100100——Visage Ventures Pty LtdAustralia100100——PME Nominees Pty Ltd (ATF Employee Share Trust)Australia100100——Pro Medicus (USA) LLCUnited States100100——Visage Ventures IncUnited States100100——Visage Imaging IncUnited States1001002,3892,389Visage Imaging GmbHGermany1001003,6383,6386,0276,027(b) Ultimate parentPro Medicus Limited is the ultimate Australian parent entity and the ultimate parent of the Group.(c) Transactions with related partiesThe following table provides the total amount of transactions that were entered into with related parties for the relevant financial year.ConsolidatedSales to related parties $000Purchases from related parties $000Other transactions with related parties $000Related partyChampagne Properties Pty Ltd – Rental lease2019—200—Champagne Properties Pty Ltd – Rental lease2018—169—* Champagne Properties Pty Ltd is an entity controlled by Directors of the Company, S. Hupert and A. Hall.Terms and conditions of transactions with related partiesSales to and purchases from related parties are made in arm’s length transactions both at normal market prices and on normal commercial terms.Outstanding balances at year end are unsecured, interest free and payable on demand. For personal use only5825. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIESThe Group’s principal financial instruments are cash and short-term deposits. The main purpose of these financial instruments is to provide finance for the Group’s operations. The Group has various other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations. The main risks arising from the Group’s financial instruments are foreign currency risk, interest risk and credit risk. The Board manages each of these risks as detailed below.Foreign currency risk(i) Functional and presentation currencyBoth the functional and presentation currency of Pro Medicus Limited and its Australian subsidiaries are Australian dollars ($). The United States subsidiaries’ functional currency is United States Dollars. The subsidiary in Germany has a functional currency of Euro. Foreign subsidiaries are translated to presentation currency for consolidated reporting.(ii) Transactions and balancesTransactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the reporting date.Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.(iii) Translation of Group Companies’ functional currency to presentation currencyThe results of the United States and German subsidiaries are translated into Australian dollars (presentation currency) using an average exchange rate for the trading period. Assets and liabilities are translated at exchange rates prevailing at reporting date.Exchange variations resulting from the translation are recognised in the foreign currency translation reserve in equity.On consolidation, exchange differences arising from the translation of the net investments in foreign subsidiaries are taken to the foreign currency translation reserve. If a foreign subsidiary were sold, the proportionate share of exchange differences would be transferred out of equity and recognised in profit or loss.The Group has transactional currency exposure, which arise from sales made in currencies other than the Group’s presentational currency.Approximately 83% (2018: 79%) of the Group’s sales are denominated in currencies other than the presentational currency, and these sales would be predominately offset by currency exposure on costs. Foreign bank accounts have also been established, to create a natural hedge and reduce the need for regular transfers from the presentational currency (AUD) cash holdings. At 30 June the Group had the following exposure to US$ foreign currency that is not designated in cash flow hedges or recorded in the functional currency of the subsidiaryConsolidated2019$’0002018$’000Financial assetsCash and cash equivalents12,8865,65212,8865,652Financial liabilitiesTrade and other payables——Net exposure12,8865,652PRO MEDICUS ANNUAL REPORT 201959At 30 June the Group had the following exposure to CAD$ foreign currency that is not designated in cash flow hedges or recorded in the functional currency of the subsidiaryConsolidated2019$’0002018$’000Financial assetsCash and cash equivalents619144619144Financial liabilitiesTrade and other payables——Net exposure619144At 30 June the Group had the following exposure to GBP£ foreign currency that is not designated in cash flow hedges or recorded in the functional currency of the subsidiaryConsolidated2019$’0002018$’000Financial assetsCash and cash equivalents126125126125Financial liabilitiesTrade and other payables——Net exposure126125At 30 June the Group had the following exposure to EUR€ foreign currency that is not designated in cash flow hedges or recorded in the functional currency of the subsidiaryConsolidated2019$’0002018$’000Financial assetsCash and cash equivalents3333Financial liabilitiesTrade and other payables——Net exposure33At 30 June, had the Australian Dollar moved, as illustrated in the table below, with all other variables held constant, post-tax profit and equity (excluding retained profits) would have been affected as follows:Post tax profithigher/(lower)Other comprehensive incomehigher/(lower)Judgements of reasonably possible movements:2019 $’0002018 $’0002019 $’0002018 $’000AUD/USD +10%(10)(565)(95)(79)AUD/USD –5%52834840AUD/CAD +10%(62)(14)——AUD/CAD –5%317——AUD/GBP +10%(13)(13)——AUD/GBP –5%66——AUD/EUR +10%——(244)(215)AUD/EUR –5%——122107Management believe the reporting date risk exposures are representative of the risk exposure inherent in the financial instruments.For personal use only6025. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (cont’d) Credit riskCredit risk arises from the financial instruments of the Group, which comprise cash and cash equivalents and trade and other receivables. The Group’s exposure to credit risk arises from potential defaults of the counter-party, with a maximum exposure equal to the carrying amount of the financial assets.The Group trades only with recognised, credit worthy third parties.It is the Group’s policy that all customers who wish to trade on credit terms are subject to credit assessment.In addition, receivable balances are monitored on an ongoing basis with the result that the Group’s exposure to bad debts is not significant.As the Group trades predominantly within the Diagnostic Imaging market there is a concentration of credit risk. Given the underlying Government funding support for Radiology in Hospital settings and the Imaging Centre and Diagnostic Imaging market, and the commercial successes achieved by the Group to date, credit risk is considered to be minimal. Cash and cash equivalents are held with several financial institutions, with the majority held with the Westpac Banking Corporation and Wells Fargo Bank N.A., both AA rated banks.Interest riskThe Group exposure to market interest rates relates primarily to the company’s cash and cash equivalents.At reporting date, the Group had the following financial assets exposed to Australian Variable interest rate risk that are not designated in cash flow hedges:Cash and Cash equivalents in the Group ($’000) $32,315 (2018: $25,238). The Group’s policy is to place cash balances in either 30-90 day term deposits or commercial bills that earn higher interest rates.At 30 June 2019, if interest rates had moved, as illustrated in the table below, with all other variables held constant, post-tax profit and equity (excluding retained profits) would have been affected as follows:ConsolidatedPost tax profithigher/(lower)Other comprehensive incomehigher/(lower)Judgements of reasonably possible movements:2019 $’0002018 $’0002019 $’0002018 $’000+1% (100 basis points)322250——–0.5% (50 basis points)(161)(125)——Liquidity riskThe Group has minimal liquidity risk as it has cash reserves of $32.2m, with no borrowings.These cash reserves are deemed to be adequate and the Board believes they will underpin the ongoing growth of the business.The table below reflects all contractually fixed pay-offs for settlement and repayments resulting from recognised financial liabilities. Cash flows for financial liabilities without fixed amount of timing are based on the conditions existing at 30 June 2019.The remaining contractual maturities of the Group’s financial liabilities are:Consolidated2019$’0002018$’000(Restated)<30 days1,3851,07431 – 60 days3446761 – 90 days29144Over 90 days1,663714TOTAL3,4211,999PRO MEDICUS ANNUAL REPORT 20196126. CONTINGENCIESTax related contingenciesAmended assessments from the Australian Taxation Office (ATO)As a result of the ATO’s program of routine and regular tax audit, the Group anticipates that ATO audits may occur in the future. The Group is similarly subject to routine tax audits in certain overseas jurisdictions. The ultimate outcome of any future tax audits cannot be determined with an acceptable degree of reliability at this time. Nevertheless, the Group believes that it is making adequate provision for its taxation liabilities (including amounts shown as deferred and current tax liabilities) and is taking reasonable steps to address potentially contentious issues with the ATO. However, there may be an impact to the Group of any of the revenue authority investigations results in an adjustment that increases the Group’s taxation liabilities.Ongoing transactions – transfer pricingThe Group has offshore operations in the United States and Germany (Note 24). There are additional Group transactions, which include the Company and its US and German based subsidiaries Visage Imaging Inc. and Visage Imaging GmbH and Pro Medicus Limited. These transactions are on an arm’s length basis and are conducted at normal market prices and on normal commercial terms.Whilst there are no investigations currently in progress, such transactions are not subject to any statutory limit in Australia. 27. PARENT ENTITY INFORMATION20192018Information relating to Pro Medicus Limited$000$000(Restated)Current assets20,87324,926Total assets33,92135,842Current liabilities21,28918,778Total liabilities24,85921,251Issued capital1,9621,962Retained earnings5,66512,629Foreign currency translation reserve(3,395)(2,944)Share reserve4,9033,018Share Buyback Reserve(73)(73)Total shareholders’ equity9,06214,592Profit/(loss) of the parent entity2,7811,432Total comprehensive income of parent entity2,7811,432The parent entity has not entered into any guarantees in relation to the debts of its subsidiaries. There are no contingent liabilities held against the parent entity. The parent entity does not have any contractual commitments for the acquisition of property, plant and equipment.For personal use only6228. OTHER ACCOUNTING POLICIES(a) Accounting Standards and Interpretation issued but not yet effectiveAustralian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the annual reporting period ending 30 June 2019. These are as follows:-i. AASB 16 Leases – Effective date: 1 January 2019 (Application date: 1 July 2019)AASB 16 replaces existing lease requirements in Australian Accounting Standards (AASB 117 Leases, Interpretation 4 Determining whether an Arrangement contains a Lease, SIC – 15 Operating Leases – Incentives, SIC – 27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease).AASB 16 requires lessees to account for all leases under a single on-balance sheet model in a similar way to finance leases under AASB 117. The standard includes two recognition exemptions for lessees – leases of ’low-value’ assets (e.g., personal computers) and short-term leases (i.e., leases with a lease term of 12 months or less). At the commencement date of a lease, a lessee will recognise a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the right-of-use asset). In determining the lease liability, the Group must consider the lease term and the expected exercise of renewal options available.Lessees will be required to separately recognise the interest expense on the lease liability and the depreciation expense on the right-of-use asset. Lessees will be required to remeasure the lease liability upon the occurrence of certain events (e.g., a change in the lease term, a change in future lease payments resulting from a change in an index or rate used to determine those payments). The lessee will generally recognise the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset.Lessor accounting is substantially unchanged from today’s accounting under AASB 117. Lessors will continue to classify all leases using the same classification principle as in AASB 117 and distinguish between two types of leases: operating and finance leases. The Group is currently assessing the impact of the change in standard, although no material impact is expected.ii. AASB Interpretation 23 Uncertainty over Income Tax Treatments – Effective date: 1 January 2019 (Application date: 1 July 2019)The Interpretation clarifies the application of the recognition and measurement criteria in AASB 12 Income Taxes when there is uncertainty over income tax treatments. The Interpretation specifically addresses the following:• Whether an entity considers uncertain tax treatments separately.• The assumptions an entity makes about the examination of tax treatments by taxation authorities.• How an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates.• How an entity considers changes in facts and circumstances.The Group is currently assessing the impact of the application of the new interpretation.iii. Conceptual Framework AASB 2019-1 Conceptual Framework for Financial Reporting Amendments to Australian Accounting Standards – Reference to the Conceptual Framework — Effective date: 1 January 2020 (Application date: 1 July 2020)The revised Conceptual Framework includes some new concepts, provides updated definitions and recognition criteria for assets and liabilities and clarifies some important concepts. It is arranged in eight chapters, as follows. • Chapter 1 — The objective of financial reporting • Chapter 2 — Qualitative characteristics of useful financial information• Chapter 3 — Financial statements and the reporting entity• Chapter 4 — The elements of financial statements• Chapter 5 — Recognition and derecognition• Chapter 6 — Measurement• Chapter 7 — Presentation and disclosure• Chapter 8 — Concepts of capital and capital maintenancePRO MEDICUS ANNUAL REPORT 201963AASB 2019-1 sets out the amendments to Australian Accounting Standards, Interpretations and other pronouncements in order to update references to the revised Conceptual Framework. The changes to the Conceptual Framework may affect the application of accounting standards in situations where no standard applies to a particular transaction or event. In addition, relief has been provided in applying AASB 3 and developing accounting policies for regulatory account balances using AASB 108, such that entities must continue to apply the definitions of an asset and a liability (and supporting concepts) in the Framework for the Preparation and Presentation of Financial Statements (July 2004), and not the definitions in the revised Conceptual Framework.The Group is currently assessing the impact of the application of the new Conceptual Framework.(b) Derivative financial instruments and hedgingThe Group uses derivative financial instruments (forward currency contracts) to manage its risks associated with foreign currency. Such derivative financial instruments are initially recognised at fair value at the date on which a derivative contract is entered into and are subsequently remeasured to fair value at the reporting date. The fair value of the derivative financial instruments are level 2, being derived from directly or indirectly observable inputs.Derivatives are carried as assets when their fair value is positive and as liabilities when their fair value is negative. Any gains or losses arising from changes in the fair value of derivative are recorded directly in profit or loss for the year within net foreign currency gains/(losses). The Group does not apply hedge accounting. The foreign exchange forward contracts are entered into for periods consistent with foreign currency exposure of the underlying transactions, generally from three to six months.Set out below is a comparison of the carrying amounts and fair value of the Group’s financial instruments.20192018CaryingAmount$’000FairValue$’000CaryingAmount$’000FairValue$’000Financial liabilities Foreign exchange forward contracts(159)(159)(193)(193)(159)(159)(193)(193)(c) Other taxesRevenues, expenses and assets are recognised net of the amount of GST except:• when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or of the expense item as applicable; and• receivables and payables are stated with the amount of GST included.The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority.(d) ComparativesWhere necessary, comparatives have been reclassified and repositioned for consistency with current year disclosures. For personal use only64DIRECTORS DECLARATIONIn accordance with a resolution of the directors of Pro Medicus Limited, I state that:(1) In the opinion of the directors: (a) the financial statements, notes and the additional disclosures included in the directors’ report designated as audited, of the consolidated entity are in accordance with the Corporations Act 2001, including: (i) giving a true and fair view of the consolidated entity’s financial position as at 30 June 2019 and of the performance for the year ended on that date; and (ii) complying with Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Regulations 2001; and (b) there are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable. (c) the financial statements and notes comply with International Financial Reporting Standards (IFRS) as disclosed in Note 2(b).(2) This declaration has been made after receiving the declarations required to be made to the directors in accordance with section 295A of the Corporations Act 2001 for the financial year ended 30 June 2019.On behalf of the BoardP T Kempen ChairmanMelbourne, 22 August 2019PRO MEDICUS ANNUAL REPORT 201965INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019For personal use only66INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019PRO MEDICUS ANNUAL REPORT 201967INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019For personal use only68INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019PRO MEDICUS ANNUAL REPORT 201969INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019For personal use only70INDEPENDENT AUDIT REPORTFOR THE YEAR ENDED 30 JUNE 2019PRO MEDICUS ANNUAL REPORT 201971Additional information required by the Australian Stock Exchange Ltd and not shown elsewhere in this report is as follows. (a) Distribution of equity securitiesThe number of shareholders, by size of holding, in each class of share are:Ordinary sharesNumber of holdersNumber of shares1 – 1,0003,8981,690,7221,001– 5,0001,9914,672,5785,001– 10,0003612,698,00310,001– 100,0002997,751,410100,001and Over3886,803,8056,587103,616,518The number of shareholders holding less than a marketable parcel are:72322(b) Twenty largest shareholdersListed ordinary sharesThe names of the twenty largest holders of quoted shares are:Number of sharesPercentage of ordinary shares1Dr S Hupert (multiple shareholdings)29,107,66028.09%2Mr A Hall (multiple shareholdings)29,067,50028.05%3HSBC Custody Nominees (Australia) Limited10,329,4629.97%4J P Morgan Nominees Australia Limited6,378,8596.16%5Citicorp Nominees Pty Ltd2,870,6492.77%6National Nominees Limited844,2550.81%7Mr Bram Vander Jagt & Mrs Maaike Vander Jagt780,0000.75%8Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen (multiple shareholdings)678,0820.65%9Grain Exporters (Australia) Pty Ltd600,5780.58%10BNP Paribas Noms Pty Ltd583,0410.56%11ECapital Nominees Pty Limited492,0960.47%12Mr Kenneth John Vander Jagt & Mrs Tanya Vander Jagt383,6000.37%13Mr Danny Tauber381,5730.37%14Mr Roderick Lyle (multiple shareholdings)340,0000.33%15Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi337,5370.33%16Mr John Charles Plummer300,0000.29%17Mr Evan Philip Clucas and Ms Leanne Jane Weston287,9800.28%18Mr Colin Gregory Organ271,0000.26%19Mr Michael Wu244,9420.24%20BNP Parabis Nominees Pty Ltd229,5650.22%84,508,37981.56%(c) Substantial shareholdersThe names of substantial shareholders who have notified the Company in accordance with section 671B of the Corporations Law are:Number of sharesS. Hupert29,107,660A Hall29,067,500(d) Voting rightsAll ordinary shares carry one vote per share without restriction.ASX ADDITIONAL INFORMATIONFor personal use only72The Board of Directors of Pro Medicus Limited is responsible for the corporate governance of the entity having regard to the ASX Corporate Governance Council (CGC) published guidelines as well as its corporate governance principles and recommendations. The Board guides and monitors the business and affairs of Pro Medicus Limited on behalf of the shareholders by whom they are elected and to whom they are accountable.The table below summaries the Group’s compliance with the CGC’s recommendations.RecommendationComplyYes/NoReference/explanationPrinciple 1 – Lay solid foundations for management and oversight1.1A listed entity should disclose:a) roles and responsibilities of its board and management; and b) those matters expressively reserved to the board and those delegated to management.YesPage 761.2A listed entity should:a) undertake appropriate checks before appointing a person, or putting forward to security holders a candidate for election, as a director; and b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.YesPage 761.3A listed entity should have written agreement with each director and senior executive setting out the terms of their agreement.NoPage 751.4The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.YesPage 761.5A listed entity should:a) have a diversity policy which includes requirements for the board or a relevant committee of the board to set measurable objectives for achieving gender diversity and to assess annually both the objectives and the entity’s progress in achieving them;b) disclose that policy or a summaryc) disclose as at the end of each reporting period the measurable objectives for achieving gender diversity set by the board or a relevant committee of the board in accordance with the entity’s diversity policy and its progress towards achieving them, and either:1) the respective proportions of men and women on the board, in senior executive positions and across the whole organisation (including how the entity has defined “senior executive” for these purposes); or2) if the entity is a “relevant employer” under the Workplace Gender Equality Act, the entity’s most recent “Gender Equality Indicators”, as defined in and published under that Act.Yes Page 761.6A listed entity should:a) have and disclose a process for periodically evaluation the performance of the board, its committees and individual directors; and b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.YesPage 761.7A listed entity should:a) have and disclose a process for periodically evaluating the performance of its senior executives; andb) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.YesPage 76CORPORATE GOVERNANCE STATEMENTFOR THE YEAR ENDED 30 JUNE 2019PRO MEDICUS ANNUAL REPORT 201973RecommendationComplyYes/NoReference/explanationPrinciple 2 – Structure the board to add value2.1The board of a listed entity should:a) have a nomination committee which:1) has at least three members, a majority of whom are independent directors; and2) is chaired by an independent directors, and disclose3) the charter of the committee;4) the members of the committee; and 5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at this meetings; orb) if it does not have a nomination committee, disclose the fact and the process it employs to address board succession issues and to ensure that the board has the appropriate skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.NoPage 772.2A listed entity should have and disclose a board skills matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.YesDirectors Report2.3A listed entity should disclose:a) the names of the directors considered by the board to be independent directors; b) if a director has an interest, position, association or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and c) the length of service of each director. YesPage 752.4A majority of the board of a listed entity should be independent directorsYesPage 752.5The chair of the board of a listed entity should be an independent directors and, in particular, should not be the same person as the CEO of the entity.YesPage 752.6A listed entity should have a program for inducting new directors and provide appropriate professional development opportunities for directors to develop and maintain the skills and knowledge needed to perform their role as a directors effectively.YesPage 75Principle 3 – Act ethically and responsibly3.1A listed entity should:a) have a code of conduct for its directors, senior executives and employees; and b) disclose that code or a summary of it.YesPage 78Principle 4 – Safeguard integrity in corporate reporting4.1The board of a listed entity should:a) have an audit committee which:1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and2) is chaired by an independent director, who is not the chair of the board; and disclose3) the charter of the committee4) the relevant qualifications and experience of the members of the committee; and5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; orb) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of external auditor and the rotation of the audit engagement partner.NoPage 77For personal use only74RecommendationComplyYes/NoReference/explanation4.2The board of a listed entity should, before it approves the entity’s financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.YesPage 784.3A listed entity that has an AGM should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.YesPage 78Principle 5 – Make timely and balanced disclosure5.1A listed entity should:a) have a written policy for complying with its continuous disclosure obligations under the Listing Rules; andb) disclose that policy or a summary of it.YesPage 78Principle 6 – Respect the rights of security holders6.1A listed entity should provide information about itself and its governance to investors via its website.YesPage 786.2A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors.YesPage 786.3A listed entity should disclose policies and progress it has in place to facilitate and encourage participation at meetings of security holders.YesPage 786.4A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.YesPage 78Principle 7 – Recognise and manage risk7.1The board of a listed entity should:a) have a committee or committees to oversee risk, each of which:1) has at least three members, a majority of whom are independent directors; and2) is chaired by an independent director; and disclose3) the charter of the committee4) the members of the committee; and5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; orb) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity’s risk management framework.NoPage 787.2The board or a committee of the board should:a) review the entity’s risk management framework at least annually to satisfy itself that it continues to be sound; andb) disclose, in relation to each reporting period, whether such a review has taken place.YesPage 787.3A listed entity should disclose:a) if it has an internal audit function, how the function is structured and what role it performs; orb) if it does not have an internal audit function, that fact and the processes it employs for evaluation and continually improving effectiveness of its risk management and internal control processesNoPage 787.4A listed entity should disclose whether it has any material exposure to economic, environmental and social sustainability risks and, if it does, how it manages or intends to manage those risks.YesPage 79PRO MEDICUS ANNUAL REPORT 201975RecommendationComplyYes/NoReference/explanationPrinciple 8 – Remunerate fairly and responsibly8.1The board of a listed entity should:a) have a remuneration committee which:1) has at least three members, a majority of whom are independent directors; and2) is chaired by an independent director; and disclose3) the charter of the committee4) the members of the committee; and5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; orif it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.NoPage 778.2A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.YesPage 778.3A listed entity which has an equity-based remuneration scheme should:a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; andb) disclose that policy or a summary of it.NoPage 77Pro Medicus Limited’s corporate governance practices were in place throughout the year ended 30 June 2019.Structure of the BoardThe skills, experience and expertise relevant to the position of director held by each director in office at the date of the annual report is included in the Directors’ Report. The composition of the Board was determined in accordance with the following principles and guidelines:• The Board should comprise at least four directors and should maintain a majority of non-executive directors, or at least a 50/50 ratio of non-executives and executive directors;• The Chairperson must be a non-executive director and not occupy the role of CEO;• The Board should comprise directors with an appropriate range of qualifications and expertise; and• The Board shall meet monthly and follow meeting guidelines set down to ensure all directors are made aware of, and have available all necessary information, to participate in an informed discussion of all agenda items.Directors of Pro Medicus Limited are considered to be independent when they are independent of management and free from any business or other relationship that could materially interfere with – or could reasonably be perceived to materially interfere with the exercise of their unfettered and independent judgement.In the context of director independence, “materiality” is considered from both the company and individual director perspective. The determination of materiality requires consideration of both quantitative and qualitative elements. An item is presumed to be quantitatively immaterial if it is equal or less than 5% of the appropriate base amount. It is presumed to be material (unless there is qualitative evidence to the contrary) if it is equal to or greater than 10% of the appropriate base amount. Qualitative factors considered include whether a relationship is strategically important, the competitive landscape, the nature of the relationship and the contractual or other arrangements governing it and other factors which point to the actual ability of the director in question to shape the direction of the company’s loyalty.In accordance with the definition of independence above, and the materiality thresholds set, the following directors of Pro Medicus Limited are considered to be independent:Name PositionP T Kempen Chairman, Non-Executive Director, Chairman Audit CommitteeA Glenning Non-Executive DirectorL Farrell Non-Executive DirectorThe Board wishes to advise that it continues to maintain responsibility for the actions of the Chief Executive Officer and any tasks delegated to the management by the Board.The appointment of appropriately skilled Non-Executive Directors, together with a broadly unchanged business base has meant one new director nomination has occurred this year. Executive Directors’ Appointment Letters have not been revised in the prescribed format as the board considered this unnecessary given For personal use only76the small number of fairly recently appointed current directors who understand their roles and responsibilities. The board has undertaken that the recommended format should be used for any future director appointments.Non-Executive Directors and senior executives have a written employment agreement with the Company setting out the terms of their appointment.Dr Sam Hupert and Mr. Anthony Hall were directors in Pro Medicus Pty Ltd since incorporation in 1983. Mr. Peter Kempen was appointed in March 2008, Mr Anthony Glenning was appointed in May 2016 and Dr Leigh Farrell was appointed in September 2017.Company SecretaryThe Company Secretary is accountable to the Board on all matters to do with the proper functioning of the Board. The Company Secretary, who is also the Chief Financial Officer, attends all Board meetings and ensures that the business at Board meetings is accurately captured in the minutes of these meetings.Board FunctionsAs the Board acts on behalf of and is accountable to the shareholders, it seeks to identify the expectations of the shareholders, as well as other regulatory and ethical expectations and obligations. In addition, the Board is responsible for identifying areas of significant business risk and ensuring arrangements are in place to adequately manage those risks. The Board seeks to discharge these responsibilities in a number of ways.The Board has delegated responsibility for the operation and administration of the group to the Chief Executive Officer and the executive team (as detailed in Note 23). The Board ensures that this team is appropriately qualified and experienced to discharge their responsibilities and has in place procedures to assess the performance of the Chief Executive and the executive team.The Board is responsible for ensuring that management’s objectives and activities are aligned with the expectations and risks identified by the Board. The Board has a number of mechanisms in place to ensure this is achieved. These mechanisms include the following:• approval of strategic plans, which encompass the entity’s vision, mission and strategy statements, designed to meet stakeholders’ needs and manage business risk;• involvement in developing the strategic plan (a dynamic document) and approving initiatives and strategies designed to ensure the continued growth and success of the entity;• overseeing implementation of operating plans and budgets by management and monitoring of progress against budget - this includes the establishment and monitoring of key performance indicators (both financial and non-financial) for all significant business processes; and• utilising appropriately skilled professionals to provide advice on relevant discussion topics and procedures to allow Directors, in the furtherance of their duties, to seek independent professional advice at the Company’s expense.PerformanceThe performance of the board and key executives is reviewed regularly against both measurable and qualitative indicators. During the reporting period the board conducted performance evaluations that involved an assessment of each board member’s and key executive’s performance against specific and measurable qualitative and quantitative performance criteria.The performance criteria against which directors and executives are assessed are aligned with the financial and non-financial objectives of Pro Medicus Limited.In order to ensure that the Board continues to discharge its responsibilities in an appropriate manner, the Chairman annually reviews the performance of all Directors who will be asked to retire from the board if not performing in a satisfactory manner.DiversityThe Group recognises the value contributed to the organisation by employing people with varying skills, cultural backgrounds, ethnicity and experience. Pro Medicus believes its diverse workforce is the key to its continued growth, improved productivity and performance.We actively value and embrace the diversity of our employees and are committed to creating an inclusive workplace where everyone is treated equally and fairly, and where discrimination, harassment and inequity are not tolerated. While Pro Medicus is committed to fostering diversity at all levels, gender diversity has been and continues to be a priority for the Group.The Group has established a diversity policy outlining the board’s measureable objectives for achieving diversity. This is assessed annually to measure the progress towards achieving those objectives.The table below outlines the diversity objectives established by the board, the steps taken during the year to achieve these objectives and the outcomes.PRO MEDICUS ANNUAL REPORT 201977ObjectivesSteps taken/OutcomeIncrease the number of women in the workforce, including senior management positions and at board level.• There were no key senior female appointments made during the year as there were no key senior appointments made during the year.• Pro Medicus did not appoint any females in managerial roles as there were no managerial appointments made during the year• As at 30 June 2019, women represented 21% in the Group’s workforce (2018:23%), 20% in key executive positions (2018:20%) and 0% at board level (2018:0%)• Women represented 18% of new hires during the year (2018:43%)For the upcoming financial year, the Group targets to increase female representation in the Group’s workforce to 25-30%Promote an inclusive culture that treats the workforce with fairness and respect.• Pro Medicus has set a zero tolerance policy against discrimination of employees at all levels. The company also provides avenues for employees to voice their concerns or report any discrimination.• No cases of discrimination were reported during the year (2018: nil).Provide career development opportunities for every employee, irrespective of any cultural, gender or other differences.• Whilst Pro Medicus place focus on gender diversity, career development opportunities are equal for all employees.• During the year, representation at training and development programs was based on performance of the employees.The achievement of the measurable objectives in the current financial year was taken into consideration in assessing bonuses for employees. The Group will continue to review and update the measureable objectives to promote diversity for the upcoming year.CommitteesDue to the small number of Directors, the Board decided it was more appropriate to handle nomination and remuneration issues at full Board level. No Committees for these functions have been established at this time. In addition the full Board handles any matters as and when they arise concerning environmental issues, occupational health and safety, finance and treasury. In order to maintain good corporate governance the Non-Executive Directors assume responsibility for determining and reviewing compensation arrangements for the Executive Directors of the Group. The Executive Directors in turn are responsible for determining and reviewing the compensation arrangements for the Non-Executive Directors. The CEO, in conjunction with the full Board reviews the terms of employment for all executives.The Board has delegated the responsibility of executive remuneration to the management who will assess the appropriateness of the nature and amount of remuneration of such executives on a periodic basis by reference to relevant employment market conditions with the overall objective of ensuring maximum stakeholder benefit from the retention of a high quality board and executive team. The Company does not have a policy in regards to whether participants are permitted to enter into transactions (whether through derivatives or otherwise) which limit the economic risk of participating in the scheme, however the Board are in the process of evaluating a policy for such issues.Strategic planning has been an important objective of the Board. Meetings are scheduled so that all Board members can attend and are conducted in an informal fashion to allow non-executive directors to gain enhanced industry, customer, product and research knowledge.Audit CommitteeThe Board has established an audit committee, which operates under a charter approved by the Board. It is the Board’s responsibility to ensure that an effective internal control framework exists within the entity. This includes internal controls to deal with both the effectiveness and efficiency of significant business processes. This also includes the safeguarding of assets, the maintenance of proper accounting records, and reliability of financial information as well as non-financial considerations such as the benchmarking of operational key performance indicators. The members of the audit committee are:P T Kempen ChairmanS A HupertA B HallA GlenningL FarrellFor personal use only78The audit committee is also responsible for nomination of the external auditor and reviewing the adequacy of the scope and quality of the annual statutory audit and half yearly audit review.Due to the small number of Directors, the Committee does not meet the requirements of Recommendation 4.1 as all members of the Board serve on the Audit Committee, whilst the Board Chairman is also the Audit Committee Chairman as his area of expertise is in Accounting and Finance.The number of meetings held and individual attendance of Committee members at those meetings are disclosed in the Directors Report. Prior to approval of the Company’s annual financial statements, the Board obtains a declaration from the Chief Executive Officer and Chief Financial Officer that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.A representative of the external auditors Ernst & Young will continue to attend the Annual General Meeting and is available to answer questions from security holders relevant to the audit.Continuous Disclosure PolicyThe board has developed a written policy to ensure compliance with the ASX Listing Rules on continuous disclosure and has adopted measures to ensure the market and shareholders are fully informed. The measures in place require all potential market sensitive matters are discussed with the Chief Executive Officer who in conjunction with the Chairman and other relevant directors decide whether to make an appropriate announcement to the market. Only nominated authorised persons have the authority to release these communications to the ASX. This policy is displayed on the company website.Shareholder Communication The Board of Directors aims to ensure that the shareholders, on behalf of whom they act, are informed of all information necessary to assess the performance of the Directors. Information is communicated to the shareholders through:• the annual report which is distributed to all shareholders registered to receive copies;• through the release of information to the market via the ASX• the annual general meeting and other meetings so called to obtain approval for Board action as appropriate;• an up to date website - www.promedicus.com.au;• email contact with registered users; and• special written communications to shareholders distributed with the dividend notifications.The company ensures that any material given to a particular group is available to all interested parties via the company website. This includes any material presented at the Annual General Meeting. Shareholders are encouraged to receive communications electronically as requested and can elect to do so through the company’s share registry.A copy of the Corporate Governance Statement is also available of the Company’s website – www.promedicus.com.au. The Company effectively facilitates two-way communication with shareholders, through six monthly investor relations roadshows and through constant investor meetings and conference calls with shareholders on request. Trading policyUnder the group’s security trading policy, an executive, director, or any employee of the group, must not trade in any securities of the parent company at any time when they are in possession of unpublished, price-sensitive information in relation to those securities.Executives, directors and employees of the group may only trade in the securities of the parent company during an open period. Only in exceptional circumstances will approval be forthcoming outside of an open period which is 30 days after:-• One day following the announcement of the half-yearly and full year results as the case may be.• One day following the holding of the annual general meeting.• One day after any other form of earnings forecast update is given to the market.As required by the ASX listing rules, the Group notifies the ASX of any transaction conducted by directors in the securities of the parent company.Code of Conduct The board has developed a “Code of Conduct”” consistent with the recommendations and details are disclosed on the company website.Risk Management Policies The Company takes a proactive approach to risk management. The Board is responsible for ensuring that risks are identified on a timely basis and that the Group’s objectives and activities are aligned with the risks identified by the Board.The Company believes that it is crucial for all Board members to participate in this process; as such the Board has not established separate committees for areas such as risk management, environmental issues, occupational health and safety or treasury.Whilst the Company has not established an internal audit function, it is committed to the identification; monitoring and management of risks associated PRO MEDICUS ANNUAL REPORT 201979with its business activities and has included in its management and reporting systems a number of risk management controls, such as:• Annual budgeting and monthly reporting systems for all operations which enable the monitoring of progress against performance targets and to evaluate trends• Guidelines and limits on capital expenditure and purchasing authority matrix• Executive approvals for staffing requirements• Detailed monthly management reports including cash flow reports, and to identify any foreign currency risks associated with contracts written in and cash being held in foreign currenciesThe Company up until late in the financial period was not exposed to any interest rate or significant currency sensitive loans or debts. Given the increase in overseas operations there is now an increased currency risk as a consequence of contracts written in and cash being held in foreign currencies. This change in risk profile has been noted by the board and action is being taken to manage this risk. The Board oversees appropriate backup procedures for important company data. Detailed annual review of insurance policies in force to ensure cover is at appropriate levels to safeguard key executives, Company assets and operations. The Board regularly considers succession planning to ensure staff of appropriate skill and experience are available to the Company. A review of the Company risk management policy was not undertaken during the year.The Board does not believe the Company has any material exposure to economic, environmental and social sustainability risks at the present time.For personal use only80CORPORATE INFORMATIONABN 25 006 194 752DirectorsThe names of the Directors of the Company in office during the year and until the date of this report arePeter Terence KempenChairman/ Non-Executive Director/Chairman Audit Committee Dr Sam Aaron Hupert Chief Executive Officer/ Managing Director Anthony Barry HallTechnology DirectorAnthony GlenningNon-Executive DirectorDr Leigh FarrellNon-Executive Director (appointed 8 September 2017)Company SecretaryClayton James HatchRegistered Office 450 Swan Street Richmond, VIC, 3121(03) 9429 8800Internet Addresswww.promedicus.com.auwww.promedicus.comwww.visageimaging.comSolicitorsSci-Law Strategies Morrison FoersterBankersWestpac Banking CorporationAuditorsErnst & YoungShare Registry Link Market Services LimitedLevel 12, 680 George StreetSydney NSW 2000AustraliaMailing address:Link Market Services LimitedLocked Bag A14Sydney South NSW 1235AustraliaT: +612 8280 7111Toll free: 1300 554 474F: +612 9287 0303F: (proxy forms only) +612 9287 0309E: registrars@linkmarketservices.com.auwww.linkmarketservices.com.auYou can do so much more onlinePRO MEDICUS ANNUAL REPORT 201981DID YOU KNOW THAT YOU CAN ACCESS – AND EVEN UPDATE – INFORMATION ABOUT YOUR HOLDINGS IN PRO MEDICUS LIMITED VIA THE INTERNET.Visit Link Market Services’ website www.linkmarketservices.com.au and access a wide variety of holding information, make some changes online or download forms. YOU CAN:• Check your current and previous holding balances• Choose your preferred annual report delivery option• Update your address details• Update your bank details• Lodge, or confirm lodgement of, your Tax File Number (TFN), Australian Business Number (ABN) or exemption• Check transaction and dividend history• Enter your email address• Check the share prices and graphs• Download a variety of instruction forms• Subscribe to email announcements.You can access this information via a security login using your Security holder Reference Number (SRN) or Holder Identification Number (HIN) as well as your surname (or company name) and postcode (must be the postcode recorded on your holding record).DON’T MISS OUT ON YOUR DIVIDENDSDividend cheques that are not banked are required to be handed over to the State Trustee under the Unclaimed Monies Act. You are reminded to bank cheques immediately.BETTER STILL, WHY NOT HAVE US DO YOUR BANKING FOR YOUWouldn’t you prefer to have immediate access to your dividend payment? Your dividend payments can be credited directly into any nominated bank, building society or credit union account in Australia as cleared funds on dividend payment date – and we will still mail [(or email if you prefer)] you a dividend advice confirming your payment details.Not only can we do your banking for you, but payment by direct credit eliminates the risk of cheque fraud.TOP 5 TIPS FOR PRO MEDICUS LIMITED INVESTORS VISITING LINK’S (OUR REGISTRY) WEBSITE1) Bookmark www.linkmarketservices. com.au – to bookmark, click on ‘Favourites’ on the menu bar at the top of your browser then select ‘Add to Favourites’2) Create a portfolio for your holding or holdings and you don’t have to remember your SRN or HIN every time you visit3) Lodge your email via the ‘Communications Options’ and benefit from the online communications options Pro Medicus Limited offers its investors4) Check out the ‘FAQs’ page (accessible via the orange menu bar) for answers to frequently asked questions5) Use the ‘Client List’ page (accessible via the orange menu bar) to link to Pro Medicus Limited website and the website of the other Link clients in which you invest.CONTACT INFORMATIONYou can also contact the Pro Medicus Limited share registry by calling +61 2 8280 7111 or Toll Free 1300 554 474For personal use only82NOTESFor personal use only) e n r u o b e M l j ( p u o r G n g i s e D n a t e a K y b d e c u d o r P d n a d e n g i s e D visit us at: promedicus.com.au promedicus.com visageimaging.com For personal use only

Continue reading text version or see original annual report in PDF format above